PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23666972-9 2013 In contrast, beta-cell glucose sensitivity (19 [12] pmol min-1 m-2 mM-1 vs 96 [73] of controls, P < .0001) rose (P = .02) only to 31 [26] at 1 year and was lower in nonremitters (16 [18]) than remitters (46 [33]). Glucose 23-30 CD59 molecule (CD59 blood group) Homo sapiens 59-64 23800880-6 2013 Metabolic rate of glucose increased similarly (~30%) in the two exercise groups in femoral skeletal muscle (MOD 24[9, 39] mumol kg-1 min-1, P = 0.004; HIGH 22[9, 35] mumol kg-1 min-1, P = 0.003) (mean[95% CI]) and in five individual femoral muscle groups but not in femoral SAT. Glucose 18-25 CD59 molecule (CD59 blood group) Homo sapiens 133-138 23780368-13 2013 However, with glucose infusion, the heart rate decreased 11 beats min-1, the peak work rate increased 12.5%, and exercise was considered easier by the patient. Glucose 14-21 CD59 molecule (CD59 blood group) Homo sapiens 66-71 22491199-6 2012 Treatment with intravenous glucose infusion improved maximal oxygen uptake from 23 to 27 mL x kg(-1) x min(-1), and maximal workload from 75 to 100 W. CONCLUSIONS: These results demonstrate that in addition to fixed weakness, neutral lipid storage disease with myopathy is also characterized by a profound block in fat oxidation, which limits exercise tolerance. Glucose 27-34 CD59 molecule (CD59 blood group) Homo sapiens 103-109 23377698-6 2013 Meta-regression analyses showed that HbA1c and fasting plasma glucose predicted the outcomes iAUC and iAUC min-1, respectively. Glucose 62-69 CD59 molecule (CD59 blood group) Homo sapiens 107-112 22453246-1 2012 PURPOSE: Current understanding of exogenous CHO metabolism during cold exposure is limited but suggests that exogenous glucose oxidation reaches a maximum of ~200 mg min(-1) at a glucose ingestion rate of 400 mg min(-1). Glucose 119-126 CD59 molecule (CD59 blood group) Homo sapiens 168-174 22453246-1 2012 PURPOSE: Current understanding of exogenous CHO metabolism during cold exposure is limited but suggests that exogenous glucose oxidation reaches a maximum of ~200 mg min(-1) at a glucose ingestion rate of 400 mg min(-1). Glucose 119-126 CD59 molecule (CD59 blood group) Homo sapiens 216-222 22453246-1 2012 PURPOSE: Current understanding of exogenous CHO metabolism during cold exposure is limited but suggests that exogenous glucose oxidation reaches a maximum of ~200 mg min(-1) at a glucose ingestion rate of 400 mg min(-1). Glucose 181-188 CD59 molecule (CD59 blood group) Homo sapiens 168-174 22453246-1 2012 PURPOSE: Current understanding of exogenous CHO metabolism during cold exposure is limited but suggests that exogenous glucose oxidation reaches a maximum of ~200 mg min(-1) at a glucose ingestion rate of 400 mg min(-1). Glucose 181-188 CD59 molecule (CD59 blood group) Homo sapiens 216-222 22453246-4 2012 Subjects consumed a (13)C-enriched CHO drink ((13)C-enriched glucose and fructose) providing 400 mg min(-1) of glucose + 400 mg min(-1) of fructose (GLU + FRU) or 800 mg min(-1) of glucose alone (GLU) after 60 min of cold exposure. Glucose 113-120 CD59 molecule (CD59 blood group) Homo sapiens 102-108 22453246-4 2012 Subjects consumed a (13)C-enriched CHO drink ((13)C-enriched glucose and fructose) providing 400 mg min(-1) of glucose + 400 mg min(-1) of fructose (GLU + FRU) or 800 mg min(-1) of glucose alone (GLU) after 60 min of cold exposure. Glucose 113-120 CD59 molecule (CD59 blood group) Homo sapiens 102-108 22468766-1 2012 When ingested at high rates (1.8-2.4 g min(-1)) in concentrated solutions, carbohydrates absorbed by multiple (e.g., fructose and glucose) vs. single intestinal transporters can increase exogenous carbohydrate oxidation and endurance performance, but their effect when ingested at lower, more realistic, rates during intermittent high-intensity endurance competition and trials is unknown. Glucose 130-137 CD59 molecule (CD59 blood group) Homo sapiens 39-46 22495590-5 2012 The glucose infusion rate (adjusted for fat free mass and circulating insulin concentration) required to maintain blood glucose concentration at 5 mmol l-1 during administration of insulin was decreased in hypoxia compared with normoxia (225 +- 23 vs. 128 +- 30 nmol (kg fat free mass)-1 pmol l-1 min-1; P =0.03), and unchanged during normoxia and sympathetic inhibition (219 +- 19; P =0.86) and hypoxia and sympathetic inhibition (169 +- 23; P =0.23). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 297-302 22278428-8 2012 RESULTS: Glucose disappearance increased from baseline (1.85 mg/kg min-1) compared with 24 h (2.01 min/kg min-1) after HyEx60 (P = 0.031). Glucose 9-16 CD59 molecule (CD59 blood group) Homo sapiens 69-74 21557013-7 2011 ss-cell glucose sensitivity doubled (37 [33] vs 18 [24] mol min-1 m-2 mM-1, p < 0.0001). Glucose 8-15 CD59 molecule (CD59 blood group) Homo sapiens 60-65 21388348-5 2011 Glucose disposal rates were restored to near normal in diabetic subjects after acipimox (6.2 +- 0.8 compared with 4.8 +- 0.6 mg kgffm-1 min-1; P<0.01; control 6.6 +- 0.5 mg kgffm-1 min-1; where ffm, is fat-free mass). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 184-189 21609293-5 2011 Glucose and GP were oxidized on average at 0.54 g min(-1) (coefficient of variation (CV) 37%) and 0.41 g min(-1) (CV 60%), respectively, which equated to a moderate (effect size) reduction of 24% (90% confidence limits: +-22%) with GP. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 50-56 21609293-5 2011 Glucose and GP were oxidized on average at 0.54 g min(-1) (coefficient of variation (CV) 37%) and 0.41 g min(-1) (CV 60%), respectively, which equated to a moderate (effect size) reduction of 24% (90% confidence limits: +-22%) with GP. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 105-111 20404763-7 2010 Both CHO treatments delivered GLU plus FRC in a ratio of 2:1 at a rate of 1.8 g min-1 (108 g h-1). Glucose 30-33 CD59 molecule (CD59 blood group) Homo sapiens 80-85 20826630-9 2010 Plasma glucose appearance rate was significantly higher (P < 0.01) in GLUFRU (91 +- 6 mumol kg-1 min-1) than in glucose alone (82 +- 9 mumol kg-1 min-1). Glucose 7-14 CD59 molecule (CD59 blood group) Homo sapiens 104-109 20826630-9 2010 Plasma glucose appearance rate was significantly higher (P < 0.01) in GLUFRU (91 +- 6 mumol kg-1 min-1) than in glucose alone (82 +- 9 mumol kg-1 min-1). Glucose 7-14 CD59 molecule (CD59 blood group) Homo sapiens 157-162 19418417-10 2009 For example, at a blood glucose concentration of 11 mmol x l(-1) renal glucose excretion ranged from 163 micromol x min(-1) to 25 micromol x min(-1) in subjects exhibiting a low to high VRT (G), thus showing a variability >factor 6. Glucose 24-31 CD59 molecule (CD59 blood group) Homo sapiens 116-122 20617825-8 2010 With the use of this microfluidic system, a total flow rate of 1.5 +/- 0.1 microL min(-1) was generated and used to deliver sinusoidal waves of glucose concentration with a median value of 11 mM and amplitude of 1 mM to a chamber that contained an islet of Langerhans loaded with the Ca(2+)-sensitive fluorophore, indo-1. Glucose 144-151 CD59 molecule (CD59 blood group) Homo sapiens 82-88 20646415-7 2010 (3) Compared with that before treatment, the glucose infusion ratio in the clamp test [(3.46 +- 1.66) mg x kg-1 x min-1 increased to (7.14 +- 2.37) mg x kg-1 x min-1] and HOMA-beta elevated, while HOMA-IR declined (P < 0.05 or 0.01 in all). Glucose 45-52 CD59 molecule (CD59 blood group) Homo sapiens 114-119 20646415-7 2010 (3) Compared with that before treatment, the glucose infusion ratio in the clamp test [(3.46 +- 1.66) mg x kg-1 x min-1 increased to (7.14 +- 2.37) mg x kg-1 x min-1] and HOMA-beta elevated, while HOMA-IR declined (P < 0.05 or 0.01 in all). Glucose 45-52 CD59 molecule (CD59 blood group) Homo sapiens 160-165 19779734-3 2010 Exogenous glucose oxidation peaked at ~200 mg min(-1) at the lowest glucose ingestion rate (~400 mg min(-1)). Glucose 10-17 CD59 molecule (CD59 blood group) Homo sapiens 46-52 19779734-3 2010 Exogenous glucose oxidation peaked at ~200 mg min(-1) at the lowest glucose ingestion rate (~400 mg min(-1)). Glucose 10-17 CD59 molecule (CD59 blood group) Homo sapiens 100-106 19779734-3 2010 Exogenous glucose oxidation peaked at ~200 mg min(-1) at the lowest glucose ingestion rate (~400 mg min(-1)). Glucose 68-75 CD59 molecule (CD59 blood group) Homo sapiens 100-106 19418417-10 2009 For example, at a blood glucose concentration of 11 mmol x l(-1) renal glucose excretion ranged from 163 micromol x min(-1) to 25 micromol x min(-1) in subjects exhibiting a low to high VRT (G), thus showing a variability >factor 6. Glucose 24-31 CD59 molecule (CD59 blood group) Homo sapiens 141-147 17704291-9 2007 Similar to wall stress, glucose uptake markedly increased vs. control (0.24 +/- 0.004 vs. 0.07 +/- 0.01 micromol x min(-1) x g(-1), P < 0.05), with no significant regional differences. Glucose 24-31 CD59 molecule (CD59 blood group) Homo sapiens 115-121 15955377-5 2005 The glucose disposal rate (M-value) was considerably lower in patients (2.4+/-1.6 mg kg-1 min-1, 0.2-8.1) compared with healthy subjects (7.1+/-0.2 mg kg-1 min-1, p<0.01). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 90-95 17717127-4 2007 Separately, using a flow cell, the glucose concentration was varied at approximately 0.17-0.28 mmol(-1) x L(-1) x min(-1), and the sensor"s ability to continuously monitor glucose was investigated over an extended period. Glucose 35-42 CD59 molecule (CD59 blood group) Homo sapiens 114-120 17425444-5 2007 RESULTS: Non-insulin-mediated glucose disposal increased during the luteal phase (0.009 +/- 0.004 min(1)) versus the follicular phase (0.005 +/- 0.003 min(1)) (P < 0.05). Glucose 30-37 CD59 molecule (CD59 blood group) Homo sapiens 98-104 17425444-5 2007 RESULTS: Non-insulin-mediated glucose disposal increased during the luteal phase (0.009 +/- 0.004 min(1)) versus the follicular phase (0.005 +/- 0.003 min(1)) (P < 0.05). Glucose 30-37 CD59 molecule (CD59 blood group) Homo sapiens 151-157 16627603-5 2006 RESULTS: As expected, increasing the blood glucose from 7.8 to 13.3 mmol l(-1) during the glucose clamps resulted in a steep increase of urinary glucose excretion from 0.06 to 0.77 mmol min(-1). Glucose 43-50 CD59 molecule (CD59 blood group) Homo sapiens 186-192 16627603-5 2006 RESULTS: As expected, increasing the blood glucose from 7.8 to 13.3 mmol l(-1) during the glucose clamps resulted in a steep increase of urinary glucose excretion from 0.06 to 0.77 mmol min(-1). Glucose 90-97 CD59 molecule (CD59 blood group) Homo sapiens 186-192 17425514-4 2007 Our results show an increase in insulin-mediated glucose disposal during euglycaemic clamp conditions that was significantly higher following the high-salt diet compared with the low-salt diet (7.41+/-0.41 compared with 6.11+/-0.40 mg x kg(-1) of body weight x min(-1) respectively; P=0.03). Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 261-267 16598851-8 2006 Calculated fat oxidation was lower during the glucose trial (0.17 +/- 0.02 vs. 0.25 +/- 0.03 g min-1, P < 0.001). Glucose 46-53 CD59 molecule (CD59 blood group) Homo sapiens 95-100 16598851-9 2006 Activation of alpha2-AMPK was attenuated in the glucose trial compared to the placebo trial (0.24 +/- 0.07 vs. 0.46 +/- 0.14 pmol mg-1 min-1, P = 0.03), whereas the alpha1-AMPK activity was not different between trials or affected by exercise. Glucose 48-55 CD59 molecule (CD59 blood group) Homo sapiens 135-140 16424718-11 2006 At day 4, insulin-mediated glucose disposal was higher in group AG (2.4 +/- 0.7 mg x kg(-1) x min(-1) glucose), with significant difference from group C (1.9 +/- 0.6 mg x kg(-1) x min(-1), p = .044). Glucose 102-109 CD59 molecule (CD59 blood group) Homo sapiens 94-100 16424718-12 2006 At day 8, glucose disposal was higher in group AG (2.2 +/- 0.7 mg x kg(-1) x min(-1) glucose), with significant difference in comparison with group C (1.2 +/- 0.6, p < .001). Glucose 10-17 CD59 molecule (CD59 blood group) Homo sapiens 77-83 16424718-12 2006 At day 8, glucose disposal was higher in group AG (2.2 +/- 0.7 mg x kg(-1) x min(-1) glucose), with significant difference in comparison with group C (1.2 +/- 0.6, p < .001). Glucose 85-92 CD59 molecule (CD59 blood group) Homo sapiens 77-83 16423629-10 2006 The IVGTT data revealed that insulin sensitivity (7.3 +/- 0.6 mU x L-1 x min-1) and glucose effectiveness (0.024 +/- 0.002 min-1) were not changed after the crossing. Glucose 84-91 CD59 molecule (CD59 blood group) Homo sapiens 123-128 16103515-2 2005 We randomly allocated 14 patients to receive intravenous glucose at 2 mg x kg(-1) x min(-1) (glucose group) starting with the surgical incision or an equivalent amount of normal saline 0.9% (control group). Glucose 57-64 CD59 molecule (CD59 blood group) Homo sapiens 84-90 15955377-5 2005 The glucose disposal rate (M-value) was considerably lower in patients (2.4+/-1.6 mg kg-1 min-1, 0.2-8.1) compared with healthy subjects (7.1+/-0.2 mg kg-1 min-1, p<0.01). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 156-161 16114550-5 2004 Both CD55 and CD59 were found in membrane proteins in control group, and medium supernatants of glucose, insulin, glucose + insulin group at 48 h after the inducement. Glucose 96-103 CD59 molecule (CD59 blood group) Homo sapiens 14-18 15809555-4 2005 In relation to exercise training status, basal glucose uptake was significantly (P<0.05) elevated by approximately 75% in the endurance-trained versus sedentary men (20.1+/-2.1 vs 11.9+/-1.9 pmol.mg protein-1.min-1, respectively). Glucose 47-54 CD59 molecule (CD59 blood group) Homo sapiens 212-217 15967908-3 2005 min(-1) of dextrose intravenously will (1) have more pronounced suppression of endogenous glucose production, leading to (2) a greater reduction in whole-body protein breakdown. Glucose 11-19 CD59 molecule (CD59 blood group) Homo sapiens 0-6 15967908-3 2005 min(-1) of dextrose intravenously will (1) have more pronounced suppression of endogenous glucose production, leading to (2) a greater reduction in whole-body protein breakdown. Glucose 90-97 CD59 molecule (CD59 blood group) Homo sapiens 0-6 15667573-5 2005 Recent in vitro evidence indicates that one of the key membrane complement regulators, CD59, is inactivated by glycation in the presence of high concentrations of glucose or other glycating sugars. Glucose 163-170 CD59 molecule (CD59 blood group) Homo sapiens 87-91 16114550-5 2004 Both CD55 and CD59 were found in membrane proteins in control group, and medium supernatants of glucose, insulin, glucose + insulin group at 48 h after the inducement. Glucose 114-121 CD59 molecule (CD59 blood group) Homo sapiens 14-18 10656171-6 1999 glucose tolerance factor KG (2.0 +/- 0.2 vs 2.2 +/- 0.1% min-1), SG (0.035 +/- 0.004 vs 0.032 +/- 0.007 min-1) and S1 [3.5 +/- 0.5 vs 3.8 +/- 0.3 10(4) min-1 (microU/mL)] were similar, both basal insulin and C-peptide exhibited a marked increase (87 +/- 8 vs 46 +/- 6 pmol/L, p = 0.0003; 637 +/- 62 vs 381 +/- 76 pmol/L, p < 0.03) demonstrating insulin resistance in basal conditions. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 57-62 12488240-9 2003 Glucose infusion, at 3 mg x kg(-1) x min(-1) in P subjects, resulted in a decrease in serine R(a) and an increase in oxidation. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 37-43 12612212-4 2003 Exogenous glucose was administered at a rate of 33 micromol x kg-1 x min-1 followed by 22 micromol x kg-1 x min-1. Glucose 10-17 CD59 molecule (CD59 blood group) Homo sapiens 69-74 12612212-7 2003 Glucose production rate increased comparably in both groups: < or =30 wk, from 6.0 +/- 4.1 to 8.8 +/- 3.4 micromol x kg-1 x min-1; >30 wk, from 7.8 +/- 4.6 to 11.6 +/- 5.2 micromol x kg-1 x min-1. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 127-132 12612212-7 2003 Glucose production rate increased comparably in both groups: < or =30 wk, from 6.0 +/- 4.1 to 8.8 +/- 3.4 micromol x kg-1 x min-1; >30 wk, from 7.8 +/- 4.6 to 11.6 +/- 5.2 micromol x kg-1 x min-1. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 196-201 12077725-5 2002 Coingestion of glucose and galactose at 33 micromol x kg(-1) x min(-1) each resulted in (1) decreased plasma galactose (0.3 +/- 0.1 mmol/L) and galactose Ra (6.4 +/- 1.8 micromol x kg(-1) x min(-1)); (2) increased plasma glucose and insulin; (3) doubling of splanchnic extraction of galactose; and (4) decreased contribution of galactose to glucose Ra (11% +/- 4%). Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 63-69 12077725-5 2002 Coingestion of glucose and galactose at 33 micromol x kg(-1) x min(-1) each resulted in (1) decreased plasma galactose (0.3 +/- 0.1 mmol/L) and galactose Ra (6.4 +/- 1.8 micromol x kg(-1) x min(-1)); (2) increased plasma glucose and insulin; (3) doubling of splanchnic extraction of galactose; and (4) decreased contribution of galactose to glucose Ra (11% +/- 4%). Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 190-196 12077725-5 2002 Coingestion of glucose and galactose at 33 micromol x kg(-1) x min(-1) each resulted in (1) decreased plasma galactose (0.3 +/- 0.1 mmol/L) and galactose Ra (6.4 +/- 1.8 micromol x kg(-1) x min(-1)); (2) increased plasma glucose and insulin; (3) doubling of splanchnic extraction of galactose; and (4) decreased contribution of galactose to glucose Ra (11% +/- 4%). Glucose 221-228 CD59 molecule (CD59 blood group) Homo sapiens 63-69 11956353-5 2002 Glucose was infused intraduodenally at a rate of either 1 or 3 kcal min(-1), for 60 min, (0-60 min) followed by 0.9 % saline for a further 60 min (60-120 min). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 68-74 11956353-9 2002 The rises in blood glucose (P < 0.01) and plasma insulin (P < 0.05) concentrations were greater during the 3 kcal min(-1) infusion. Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 120-126 11788655-2 2002 Insulin-stimulated glucose uptake was decreased both in the diabetic and nondiabetic twin, compared with healthy control subjects (5.2 +/- 0.7 and 8.5 +/- 0.8 vs. 11.4 +/- 0.9 mg/kg x min(-1); P < 0.01 and P < 0.02, respectively). Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 184-190 11522675-7 2001 Renal glucose balance switched from a mean +/- SE baseline net uptake of 0.6 +/- 0.4 to a net output of 4.5 +/- 1.3 micromol x kg(-1) x min(-1) in normal subjects, but in patients with diabetes there was no net renal contribution to blood glucose during similar hypoglycemia (mean +/- SE net glucose uptake [baseline 0.7 +/- 0.4] remained at 0.4 +/- 0.3 micromol x kg(-1) x min(-1) in the final 40 min of hypoglycemia; P < 0.01 between groups). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 136-142 11522675-7 2001 Renal glucose balance switched from a mean +/- SE baseline net uptake of 0.6 +/- 0.4 to a net output of 4.5 +/- 1.3 micromol x kg(-1) x min(-1) in normal subjects, but in patients with diabetes there was no net renal contribution to blood glucose during similar hypoglycemia (mean +/- SE net glucose uptake [baseline 0.7 +/- 0.4] remained at 0.4 +/- 0.3 micromol x kg(-1) x min(-1) in the final 40 min of hypoglycemia; P < 0.01 between groups). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 374-380 11277381-8 2001 Reducing glucose infusion resulted in a steep increase in glycogenolysis and gluconeogenesis, maintaining total glucose turnover (production plus infusion) constant at +/-9 mg x kg(-1) x min(-1) (+/-60% gluconeogenesis, +/-40% glycogenolysis). Glucose 9-16 CD59 molecule (CD59 blood group) Homo sapiens 187-193 11153615-12 2000 Endogenous glucose production was markedly increased in the patients (1.95 +/- 0.26 vs. 5.3 +/- 3.0 mg x kg(-1) x min(-1); p < .05 [10.8 +/- 1.4 vs. 29.4 +/- 16.7 micromol x kg(-1) x min(-1)]), whereas net carbohydrate oxidation was not different (1.7 +/- 0.5 vs. 1.3 +/- 0.3 mg x kg(-1) x min(-1) [9.4 +/- 2.8 vs. 7.2 +/- 1.7 micromol x kg(-1) x min(-1)]). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 114-120 11153615-12 2000 Endogenous glucose production was markedly increased in the patients (1.95 +/- 0.26 vs. 5.3 +/- 3.0 mg x kg(-1) x min(-1); p < .05 [10.8 +/- 1.4 vs. 29.4 +/- 16.7 micromol x kg(-1) x min(-1)]), whereas net carbohydrate oxidation was not different (1.7 +/- 0.5 vs. 1.3 +/- 0.3 mg x kg(-1) x min(-1) [9.4 +/- 2.8 vs. 7.2 +/- 1.7 micromol x kg(-1) x min(-1)]). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 186-192 11153615-12 2000 Endogenous glucose production was markedly increased in the patients (1.95 +/- 0.26 vs. 5.3 +/- 3.0 mg x kg(-1) x min(-1); p < .05 [10.8 +/- 1.4 vs. 29.4 +/- 16.7 micromol x kg(-1) x min(-1)]), whereas net carbohydrate oxidation was not different (1.7 +/- 0.5 vs. 1.3 +/- 0.3 mg x kg(-1) x min(-1) [9.4 +/- 2.8 vs. 7.2 +/- 1.7 micromol x kg(-1) x min(-1)]). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 186-192 11153615-12 2000 Endogenous glucose production was markedly increased in the patients (1.95 +/- 0.26 vs. 5.3 +/- 3.0 mg x kg(-1) x min(-1); p < .05 [10.8 +/- 1.4 vs. 29.4 +/- 16.7 micromol x kg(-1) x min(-1)]), whereas net carbohydrate oxidation was not different (1.7 +/- 0.5 vs. 1.3 +/- 0.3 mg x kg(-1) x min(-1) [9.4 +/- 2.8 vs. 7.2 +/- 1.7 micromol x kg(-1) x min(-1)]). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 186-192 11118008-5 2000 The rate of glucose production was twice as high in the diabetic subjects as in control subjects (0.70 +/- 0.05 vs. 0.36 +/- 0.03 mmol x m(-2) min(-1), P < 0.0001). Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 143-149 15354037-2 2004 Recent studies from our laboratory have shown that a mixture of glucose and sucrose or glucose and fructose ingested at a high rate (1.8 g x min(-1)) leads to peak oxidation rates of approximately 1.3 g x min(-1) and results in approximately 20 to 55% higher exogenous CHO oxidation rates compared with the ingestion of an isocaloric amount of glucose. Glucose 64-71 CD59 molecule (CD59 blood group) Homo sapiens 141-147 15354037-2 2004 Recent studies from our laboratory have shown that a mixture of glucose and sucrose or glucose and fructose ingested at a high rate (1.8 g x min(-1)) leads to peak oxidation rates of approximately 1.3 g x min(-1) and results in approximately 20 to 55% higher exogenous CHO oxidation rates compared with the ingestion of an isocaloric amount of glucose. Glucose 64-71 CD59 molecule (CD59 blood group) Homo sapiens 205-211 15354037-2 2004 Recent studies from our laboratory have shown that a mixture of glucose and sucrose or glucose and fructose ingested at a high rate (1.8 g x min(-1)) leads to peak oxidation rates of approximately 1.3 g x min(-1) and results in approximately 20 to 55% higher exogenous CHO oxidation rates compared with the ingestion of an isocaloric amount of glucose. Glucose 87-94 CD59 molecule (CD59 blood group) Homo sapiens 141-147 15354037-2 2004 Recent studies from our laboratory have shown that a mixture of glucose and sucrose or glucose and fructose ingested at a high rate (1.8 g x min(-1)) leads to peak oxidation rates of approximately 1.3 g x min(-1) and results in approximately 20 to 55% higher exogenous CHO oxidation rates compared with the ingestion of an isocaloric amount of glucose. Glucose 87-94 CD59 molecule (CD59 blood group) Homo sapiens 205-211 15354037-2 2004 Recent studies from our laboratory have shown that a mixture of glucose and sucrose or glucose and fructose ingested at a high rate (1.8 g x min(-1)) leads to peak oxidation rates of approximately 1.3 g x min(-1) and results in approximately 20 to 55% higher exogenous CHO oxidation rates compared with the ingestion of an isocaloric amount of glucose. Glucose 87-94 CD59 molecule (CD59 blood group) Homo sapiens 141-147 15354037-2 2004 Recent studies from our laboratory have shown that a mixture of glucose and sucrose or glucose and fructose ingested at a high rate (1.8 g x min(-1)) leads to peak oxidation rates of approximately 1.3 g x min(-1) and results in approximately 20 to 55% higher exogenous CHO oxidation rates compared with the ingestion of an isocaloric amount of glucose. Glucose 87-94 CD59 molecule (CD59 blood group) Homo sapiens 205-211 15354037-3 2004 PURPOSE: The purpose of the present study was to examine whether a mixture of glucose, sucrose and fructose ingested at a high rate would result in even higher exogenous CHO oxidation rates (>1.3 g x min(-1)). Glucose 78-85 CD59 molecule (CD59 blood group) Homo sapiens 203-209 15354037-7 2004 CONCLUSION: When glucose, fructose and sucrose are ingested simultaneously at high rates (2.4 g x min(-1)) during cycling exercise, exogenous CHO oxidation rates can reach peak values of approximately 1.7 g x min(-1) and estimated endogenous CHO oxidation is reduced compared with the ingestion of an isocaloric amount of glucose. Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 98-104 15354037-7 2004 CONCLUSION: When glucose, fructose and sucrose are ingested simultaneously at high rates (2.4 g x min(-1)) during cycling exercise, exogenous CHO oxidation rates can reach peak values of approximately 1.7 g x min(-1) and estimated endogenous CHO oxidation is reduced compared with the ingestion of an isocaloric amount of glucose. Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 209-215 15138838-4 2004 The rate of exogenous glucose oxidation was approximately 45% lower in women than men (0.5 and 0.6 g min(-1) vs 0.7 and 0.9 g min(-1), between min 40 and 80, and min 80 and 120, respectively). Glucose 22-29 CD59 molecule (CD59 blood group) Homo sapiens 101-107 15138838-4 2004 The rate of exogenous glucose oxidation was approximately 45% lower in women than men (0.5 and 0.6 g min(-1) vs 0.7 and 0.9 g min(-1), between min 40 and 80, and min 80 and 120, respectively). Glucose 22-29 CD59 molecule (CD59 blood group) Homo sapiens 126-132 12637983-3 2003 On one occasion, plasma glucose was decreased at the rate of 0.1+/-0.003 mmol x min(-1) x l(-1) (fast fall), on the other at the rate of 0.03+/-0.001 mmol x min(-1) x l(-1) (slow fall). Glucose 24-31 CD59 molecule (CD59 blood group) Homo sapiens 80-86 11679448-2 2001 Therefore, we tested the hypothesis that short-term (4 weeks) moderate energy restriction (-750 kcal/day) would result in a significant increase in insulin-stimulated glucose disposal (40 mU x m(-2) x min(-1) hyperinsulinemic-euglycemic clamp) in moderately overweight postmenopausal women and that when combined with resistance training (RT) an even greater effect would be seen. Glucose 167-174 CD59 molecule (CD59 blood group) Homo sapiens 201-207 11016453-4 2000 Endogenous glucose production (EGP) was 22 +/- 2, 18 +/- 2, 17 +/- 2, and 22 +/- 2 pmol x kg(-1) lean body mass (LBM) x min(-1) (P < 0.05, days 5 and 10 vs. baseline). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 120-126 10990082-5 2000 RESULTS: High concentrations of glucose decreased the expression of CD59 and CD55 by endothelial cells in a time-dependent and glucose concentration-dependent manner without affecting CD46 expression. Glucose 32-39 CD59 molecule (CD59 blood group) Homo sapiens 68-72 10990082-6 2000 High concentrations of soluble CD59 were found in the supernatants of cells treated with high glucose. Glucose 94-101 CD59 molecule (CD59 blood group) Homo sapiens 31-35 10990082-7 2000 The decrease in CD59 expression induced by high glucose concentrations was reversed by coincubation of cells with a calcium channel blocking agent (Verapamil). Glucose 48-55 CD59 molecule (CD59 blood group) Homo sapiens 16-20 10662708-8 2000 At rest after training, the percentage of glucose rate of appearance (R(a)) from GNG more than doubled (1.98 +/- 0.5% pretraining; 5.45 +/- 1.3% posttraining), as did the rate of GNG (0.11 +/- 0.03 mg x kg(-1) x min(-1) pretraining, 0.24 +/- 0.06 mg x kg(-1) x min(-1) posttraining). Glucose 42-49 CD59 molecule (CD59 blood group) Homo sapiens 212-218 10662708-8 2000 At rest after training, the percentage of glucose rate of appearance (R(a)) from GNG more than doubled (1.98 +/- 0.5% pretraining; 5.45 +/- 1.3% posttraining), as did the rate of GNG (0.11 +/- 0.03 mg x kg(-1) x min(-1) pretraining, 0.24 +/- 0.06 mg x kg(-1) x min(-1) posttraining). Glucose 42-49 CD59 molecule (CD59 blood group) Homo sapiens 261-267 10656171-6 1999 glucose tolerance factor KG (2.0 +/- 0.2 vs 2.2 +/- 0.1% min-1), SG (0.035 +/- 0.004 vs 0.032 +/- 0.007 min-1) and S1 [3.5 +/- 0.5 vs 3.8 +/- 0.3 10(4) min-1 (microU/mL)] were similar, both basal insulin and C-peptide exhibited a marked increase (87 +/- 8 vs 46 +/- 6 pmol/L, p = 0.0003; 637 +/- 62 vs 381 +/- 76 pmol/L, p < 0.03) demonstrating insulin resistance in basal conditions. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 104-109 10656171-6 1999 glucose tolerance factor KG (2.0 +/- 0.2 vs 2.2 +/- 0.1% min-1), SG (0.035 +/- 0.004 vs 0.032 +/- 0.007 min-1) and S1 [3.5 +/- 0.5 vs 3.8 +/- 0.3 10(4) min-1 (microU/mL)] were similar, both basal insulin and C-peptide exhibited a marked increase (87 +/- 8 vs 46 +/- 6 pmol/L, p = 0.0003; 637 +/- 62 vs 381 +/- 76 pmol/L, p < 0.03) demonstrating insulin resistance in basal conditions. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 104-109 10368358-6 1999 The 56% increase in glucose uptake after ET (4.95 +/- 0.90 vs. 7.74 +/- 0.82 mg. min-1. Glucose 20-27 CD59 molecule (CD59 blood group) Homo sapiens 81-86 10488706-6 1999 Peripheral glucose uptake in liver cirrhosis was 6.1+/-0.7 mg x kg(-1) x min(-1), which was lower than that in healthy volunteers (10.5+/-0.9 mg x kg(-1) x min(-1), p<0.05) and in chronic active hepatitis (8.4+/-0.3 mg x kg(-1) x min(-1), p<0.05). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 73-79 10488706-6 1999 Peripheral glucose uptake in liver cirrhosis was 6.1+/-0.7 mg x kg(-1) x min(-1), which was lower than that in healthy volunteers (10.5+/-0.9 mg x kg(-1) x min(-1), p<0.05) and in chronic active hepatitis (8.4+/-0.3 mg x kg(-1) x min(-1), p<0.05). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 156-162 10488706-6 1999 Peripheral glucose uptake in liver cirrhosis was 6.1+/-0.7 mg x kg(-1) x min(-1), which was lower than that in healthy volunteers (10.5+/-0.9 mg x kg(-1) x min(-1), p<0.05) and in chronic active hepatitis (8.4+/-0.3 mg x kg(-1) x min(-1), p<0.05). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 156-162 10050023-9 1999 After 120 min Ra and rate of disappearance (Rd) of glucose were 51-52 micromol kg-1 min-1 during Fast, 73-74 micromol kg-1 min-1 during Lo-Glu and 117-119 micromol kg-1 min-1 during Hi-Glu. Glucose 51-58 CD59 molecule (CD59 blood group) Homo sapiens 84-89 10457152-4 1999 RESULTS: The permeability-surface area product (PS) for glucose transport from the blood into the brain, PS1, was 0.145 (0.102-0.211) (median and quartiles), 0.146 (0.113-0.259), and 0.157 (0.133-0.181) ml g-1 min-1 before, during, and after insulin challenge, respectively. Glucose 56-63 CD59 molecule (CD59 blood group) Homo sapiens 210-215 10457152-5 1999 In six of the subjects, PS for transport from brain to blood over the brain glucose distribution volume, PS2/Ve decreased under hyperinsulinemia, from a baseline value of 6.56 (3.0-14.9) to 3.86 (1.41-5.32), and restored to a value of 3.8 (2.8-12.1) min-1 after insulin challenge. Glucose 76-83 CD59 molecule (CD59 blood group) Homo sapiens 250-255 10476312-5 1999 This was also confirmed in the FSIGT where the glucose tolerance index (KG) was 0.6 +/- 0.1% min-1 in D vs 1.8 +/- 0.2 in C and 1.5 +/- 0.2 in E (p < 0.0002). Glucose 47-54 CD59 molecule (CD59 blood group) Homo sapiens 93-98 10050023-9 1999 After 120 min Ra and rate of disappearance (Rd) of glucose were 51-52 micromol kg-1 min-1 during Fast, 73-74 micromol kg-1 min-1 during Lo-Glu and 117-119 micromol kg-1 min-1 during Hi-Glu. Glucose 51-58 CD59 molecule (CD59 blood group) Homo sapiens 123-128 10050023-9 1999 After 120 min Ra and rate of disappearance (Rd) of glucose were 51-52 micromol kg-1 min-1 during Fast, 73-74 micromol kg-1 min-1 during Lo-Glu and 117-119 micromol kg-1 min-1 during Hi-Glu. Glucose 51-58 CD59 molecule (CD59 blood group) Homo sapiens 123-128 9755482-1 1998 Washed human erythrocytes incubated with glucose and S8 and purged with N2 produced H2S at a nearly constant rate of 170 mumol (L cells)-1 min-1, which continued for several hours. Glucose 41-48 CD59 molecule (CD59 blood group) Homo sapiens 139-144 10334304-2 1999 In the postabsorptive state, the rate of glucose appearance was 11.5 +/- 0.6 micromol x kg(-1) x min(-1). Glucose 41-48 CD59 molecule (CD59 blood group) Homo sapiens 97-103 10334304-3 1999 Hepatic glucose production, calculated as the sum of net glucose output (9.8 +/- 0.8 micromol x kg(-1) x min(-1)) and splanchnic glucose uptake (2.2 +/- 0.3 micromol x kg(-1) x min(-1)) accounted for the entire rate of glucose appearance. Glucose 8-15 CD59 molecule (CD59 blood group) Homo sapiens 105-111 10334304-6 1999 In the 60-h fasted state, the rate of glucose appearance was 8.2 +/- 0.3 micromol x kg(-1) x min(-1). Glucose 38-45 CD59 molecule (CD59 blood group) Homo sapiens 93-99 9762405-2 1998 The values are estimated as the initial velocity (V) expressed in eta 14CO2 x min-1 x g-1 of fresh tissues by [U-14C] glucose metabolism. Glucose 118-125 CD59 molecule (CD59 blood group) Homo sapiens 78-83 9754970-6 1998 Mean post-absorptive glucose oxidation rose from 126 (SEM 15) mg x min(-1) (day 0) to 164 (SEM 14) mg x min(-1) (day 8, P = 0.04) and 160 (SEM 20) mg x min(-1) (day 40, P = 0.07). Glucose 21-28 CD59 molecule (CD59 blood group) Homo sapiens 67-73 9754970-6 1998 Mean post-absorptive glucose oxidation rose from 126 (SEM 15) mg x min(-1) (day 0) to 164 (SEM 14) mg x min(-1) (day 8, P = 0.04) and 160 (SEM 20) mg x min(-1) (day 40, P = 0.07). Glucose 21-28 CD59 molecule (CD59 blood group) Homo sapiens 104-110 9754970-6 1998 Mean post-absorptive glucose oxidation rose from 126 (SEM 15) mg x min(-1) (day 0) to 164 (SEM 14) mg x min(-1) (day 8, P = 0.04) and 160 (SEM 20) mg x min(-1) (day 40, P = 0.07). Glucose 21-28 CD59 molecule (CD59 blood group) Homo sapiens 104-110 9481683-4 1998 The increase in the Vmax for L-arginine transport (9.0 +/- 1.1) pmol (micrograms protein)-1 min-1) in diabetic endothelial cells cultured in 5 mM D-glucose was unaffected following 24 h exposure to 25 mM D-glucose. Glucose 146-155 CD59 molecule (CD59 blood group) Homo sapiens 92-97 9536926-8 1998 The glucose infusion rate was significantly increased after infusion of NG-monomethyl L-arginine (8.9 +/- 0.9 compared with 7.9 +/- 0.8 mg min-1 kg-1 for placebo; P = 0.002). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 139-149 9536926-9 1998 Whole-body glucose uptake increased during the clamp, with values of 9.4 +/- 0.7 and 10.9 +/- 0.8 mg min-1 kg-1 for placebo and NG-monomethyl L-arginine respectively (P = 0.036; 95% confidence interval 0.2,2.8). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 101-111 9701703-2 1998 Administration of a single dose of glucagon (0.1 mg/kg) caused an increase in glucose production rate by near 140% from 4.2 to 10.1 mg.kg-1.min-1. Glucose 78-85 CD59 molecule (CD59 blood group) Homo sapiens 140-145 9701703-5 1998 The amount of glycerol converted to glucose by gluconeogenesis was 9.1 micromol.kg-1.min-1 before and 10.5 micromol. Glucose 36-43 CD59 molecule (CD59 blood group) Homo sapiens 85-90 9711998-5 1998 In the same subjects, GSH infusion significantly increased total glucose uptake (from 37.1 +/- 6.7 micromol kg(-1) x min(-1) to 39.5 +/- 7.7 micromol x kg(-1) x min(-1), P < .05), whereas saline infusion was completely ineffective. Glucose 65-72 CD59 molecule (CD59 blood group) Homo sapiens 117-123 9711998-7 1998 Similar findings were found in diabetic patients, in whom GSH infusion significantly increased both total glucose uptake (from 25.3 +/- 9.0 micromol x kg(-1) x min(-1) to 31.4 +/- 10.0 micromol x kg(-1) x min(-1), P < .001) and intraerythrocytic GSH/GSSG ratio (from 14.8 +/- 4.1 to 21.7 +/- 6.7, P < .01). Glucose 106-113 CD59 molecule (CD59 blood group) Homo sapiens 160-166 9768373-3 1998 The glucose infusion rate (GIR) was determined by glucose clamp procedure at an insulin infusion rate of 40 mU m-2 min-1 (plasma insulin concentrations: 700-800 pmol l-1). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 115-120 9661121-1 1998 BACKGROUND: During periods in which nutrition support of critically ill young children must be parenteral, glucose infusions are administered at up to 10 or more mg.kg-1.min-1 to meet predicted energy needs. Glucose 107-114 CD59 molecule (CD59 blood group) Homo sapiens 170-175 9661121-9 1998 Although there was a significantly increased level of total glucose oxidation (3.2 to 3.8 mg.kg-1.min-1), this increment (29% +/- 9%) was accompanied by a significant decrease in the efficiency of energy production, because the bulk of the additional glucose above 5 mg.kg-1.min-1 was not being oxidized. Glucose 60-67 CD59 molecule (CD59 blood group) Homo sapiens 98-103 9661121-11 1998 CONCLUSIONS: Maximum glucose oxidation in severely burned children occurs at intakes approximating 5 mg.kg-1.min-1. Glucose 21-28 CD59 molecule (CD59 blood group) Homo sapiens 109-114 9539195-5 1998 RESULTS: The obese group presented hyperinsulinaemia in the basal state and after glucose loading (insulin area = 58+/-5 vs 33+/-3 nmol x I[-1] x 2 h, P = 0.005), insulin resistance (M value = 37.4+/-4.8 vs 50.6+/-2.6 micromol x min[-1] x kg FFM[-1], P = 0.002), and insulin hypersecretion (61.9+/-6.0 vs 33.9 +/- 4.0 nmol x 2 h, P = 0.007); endogenous glucose production was similar in the two groups. Glucose 82-89 CD59 molecule (CD59 blood group) Homo sapiens 229-235 9104876-4 1997 Pretraining, the intensity effect on glucose kinetics was evident with rates of appearance (R(a); 5.84 +/- 0.23 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1)), disappearance (R(d); 5.78 +/- 0.19 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1) x min(-1)), oxidation (R(ox); 5.36 +/- 0.15 vs. 3.41 +/- 0.23 mg x kg(-1) x min(-1)), and metabolic clearance (7.03 +/- 0.56 vs. 5.20 +/- 0.28 ml x kg(-1) x min(-1)) of glucose being significantly greater (P < or = 0.05) in the 65% than the 45% VO2peak trial. Glucose 37-44 CD59 molecule (CD59 blood group) Homo sapiens 144-150 9329954-6 1997 Whole body insulin-stimulated glucose uptake was decreased in the patients (15.6+/-2.1 vs. 23.1+/-2.0 micromol x kg-1 x min-1). Glucose 30-37 CD59 molecule (CD59 blood group) Homo sapiens 120-125 9445538-7 1997 In anoxic chemostats with a mixture of formate and glucose as the carbon and electron source, C2Cl4 was transformed at high rates (above 140 micromol 1-1 h-1, corresponding to 145 nmol Cl- min-1 mg protein-1), into cis-C2H2Cl2 and C2H3Cl. Glucose 51-58 CD59 molecule (CD59 blood group) Homo sapiens 189-194 9104876-4 1997 Pretraining, the intensity effect on glucose kinetics was evident with rates of appearance (R(a); 5.84 +/- 0.23 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1)), disappearance (R(d); 5.78 +/- 0.19 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1) x min(-1)), oxidation (R(ox); 5.36 +/- 0.15 vs. 3.41 +/- 0.23 mg x kg(-1) x min(-1)), and metabolic clearance (7.03 +/- 0.56 vs. 5.20 +/- 0.28 ml x kg(-1) x min(-1)) of glucose being significantly greater (P < or = 0.05) in the 65% than the 45% VO2peak trial. Glucose 37-44 CD59 molecule (CD59 blood group) Homo sapiens 221-227 9104876-4 1997 Pretraining, the intensity effect on glucose kinetics was evident with rates of appearance (R(a); 5.84 +/- 0.23 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1)), disappearance (R(d); 5.78 +/- 0.19 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1) x min(-1)), oxidation (R(ox); 5.36 +/- 0.15 vs. 3.41 +/- 0.23 mg x kg(-1) x min(-1)), and metabolic clearance (7.03 +/- 0.56 vs. 5.20 +/- 0.28 ml x kg(-1) x min(-1)) of glucose being significantly greater (P < or = 0.05) in the 65% than the 45% VO2peak trial. Glucose 37-44 CD59 molecule (CD59 blood group) Homo sapiens 221-227 9104876-4 1997 Pretraining, the intensity effect on glucose kinetics was evident with rates of appearance (R(a); 5.84 +/- 0.23 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1)), disappearance (R(d); 5.78 +/- 0.19 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1) x min(-1)), oxidation (R(ox); 5.36 +/- 0.15 vs. 3.41 +/- 0.23 mg x kg(-1) x min(-1)), and metabolic clearance (7.03 +/- 0.56 vs. 5.20 +/- 0.28 ml x kg(-1) x min(-1)) of glucose being significantly greater (P < or = 0.05) in the 65% than the 45% VO2peak trial. Glucose 37-44 CD59 molecule (CD59 blood group) Homo sapiens 221-227 9104876-4 1997 Pretraining, the intensity effect on glucose kinetics was evident with rates of appearance (R(a); 5.84 +/- 0.23 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1)), disappearance (R(d); 5.78 +/- 0.19 vs. 4.73 +/- 0.19 mg x kg(-1) x min(-1) x min(-1)), oxidation (R(ox); 5.36 +/- 0.15 vs. 3.41 +/- 0.23 mg x kg(-1) x min(-1)), and metabolic clearance (7.03 +/- 0.56 vs. 5.20 +/- 0.28 ml x kg(-1) x min(-1)) of glucose being significantly greater (P < or = 0.05) in the 65% than the 45% VO2peak trial. Glucose 37-44 CD59 molecule (CD59 blood group) Homo sapiens 221-227 9124550-4 1997 Formation of glucose from alanine was also stimulated (0.52 +/- 0.05 vs. 0.75 +/- 0.04 micromol x kg(-1) x min(-1); P < 0.001) in the absence of a change in plasma alanine concentration. Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 107-113 9143862-10 1997 Insulin-stimulated glucose uptake was reduced by 46% in the whole body, from 39 to 21 mumol.kg-1.min-1 and by 59% in the femoral muscles, from 99 to 41 mumol.kg-1.min-1, with celiprolol as compared to saline. Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 97-102 9143862-10 1997 Insulin-stimulated glucose uptake was reduced by 46% in the whole body, from 39 to 21 mumol.kg-1.min-1 and by 59% in the femoral muscles, from 99 to 41 mumol.kg-1.min-1, with celiprolol as compared to saline. Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 163-168 8889439-7 1996 In 10 out of these 15 individuals, the forearm glucose uptake was further increased in a second, separate, repeat experiment with concomitant intra-arterial infusion of glucose 5% (0.2 mL dL-1 min-1), resulting in forearm venous glucose concentrations of approximately 15 mmol L-1. Glucose 169-176 CD59 molecule (CD59 blood group) Homo sapiens 193-198 8955462-6 1996 The hepatic glucose production rate averaged 25.0 +/- 3.5 mumol.kg-1 min-1 (4.5 +/- 0.6 mg.kg-1.min-1) and the endogenous plasma appearance rate of glycerol 8.7 +/- 1.2 mumol.kg-1.min. Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 69-74 8955462-6 1996 The hepatic glucose production rate averaged 25.0 +/- 3.5 mumol.kg-1 min-1 (4.5 +/- 0.6 mg.kg-1.min-1) and the endogenous plasma appearance rate of glycerol 8.7 +/- 1.2 mumol.kg-1.min. Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 96-101 8903329-8 1996 Whole-body glucose uptake was 37+/-4 micromol x min(-1) x kg(-1) in controls and 14+/-2 mciromol x min(-1) x kg(-1) in patients (P = 0.001). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 48-54 8889439-7 1996 In 10 out of these 15 individuals, the forearm glucose uptake was further increased in a second, separate, repeat experiment with concomitant intra-arterial infusion of glucose 5% (0.2 mL dL-1 min-1), resulting in forearm venous glucose concentrations of approximately 15 mmol L-1. Glucose 169-176 CD59 molecule (CD59 blood group) Homo sapiens 193-198 8865083-11 1996 The glucose infusion rate (GIR) necessary to maintain euglycaemia during maximal insulin stimulation was lower during PEC compared with CC (15.7%, 81.3 +/- 3.2 vs. 96.4 +/- 8.8 mumol kg-1 min-1, P < 0.05). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 188-193 8864417-5 1996 Insulin infusion (7 pmol min-1 kg-1) promoted similar glucose utilization in the hypertensives and normotensives: 24.8 +/- 2.3 vs. 26.0 +/- 3.0 mumol min-1 kg-1 respectively. Glucose 54-61 CD59 molecule (CD59 blood group) Homo sapiens 25-35 8621747-4 1996 The fit of the integrated symmetric Michaelis-Menten model to the time course of relative glucose signals yielded an estimated plasma glucose concentration for half maximal transport, Kt, of 4.8 +/- 2.4 mM (mean +/- SD), a maximal transport rate, Tmax, of 0.80 +/- 0.45 micromol g-1 min-1, and a cerebral metabolic glucose consumption rate (CMR)glc of 0.32 +/- 0.16 micromol g-1 min-1. Glucose 134-141 CD59 molecule (CD59 blood group) Homo sapiens 283-288 8737024-3 1996 Whole blood glucose concentrations were measured contemporaneously and the rate of plasma glucose decline (mmol l-1 min-1) for each test was estimated from unlogged venous plasma glucose concentrations measured at 1 min intervals. Glucose 90-97 CD59 molecule (CD59 blood group) Homo sapiens 116-121 8737024-3 1996 Whole blood glucose concentrations were measured contemporaneously and the rate of plasma glucose decline (mmol l-1 min-1) for each test was estimated from unlogged venous plasma glucose concentrations measured at 1 min intervals. Glucose 90-97 CD59 molecule (CD59 blood group) Homo sapiens 116-121 8737024-4 1996 The mean rates of plasma glucose decline for the 0.1 U kg-1 and 0.05 U kg-1 insulin doses were 0.26 mmol l-1 min-1 (n = 11, range = 0.17-0.41, intrasubject coefficient of variation (CV) = 9.4%) and 0.25 mmol l-1 min-1 (n = 6, range 0.19-0.46, intrasubject CV = 15.9%), respectively. Glucose 25-32 CD59 molecule (CD59 blood group) Homo sapiens 109-114 8800366-6 1996 The metabolic clearance rate of glucose (MCR) for the diabetic rats receiving C-peptide (12.0 +/- 1.0 mL kg-1 min-1) was significantly (P < 0.01) higher than that in the diabetic rats given saline (6.3 +/- 0.7 mL kg-1 min-1) or a randomly scrambled C-peptide (7.8 +/- 1.3 mL kg-1 min-1) at low-dose insulin infusion but not at the high-dose insulin infusion. Glucose 32-39 CD59 molecule (CD59 blood group) Homo sapiens 110-115 8800366-6 1996 The metabolic clearance rate of glucose (MCR) for the diabetic rats receiving C-peptide (12.0 +/- 1.0 mL kg-1 min-1) was significantly (P < 0.01) higher than that in the diabetic rats given saline (6.3 +/- 0.7 mL kg-1 min-1) or a randomly scrambled C-peptide (7.8 +/- 1.3 mL kg-1 min-1) at low-dose insulin infusion but not at the high-dose insulin infusion. Glucose 32-39 CD59 molecule (CD59 blood group) Homo sapiens 221-226 8800366-6 1996 The metabolic clearance rate of glucose (MCR) for the diabetic rats receiving C-peptide (12.0 +/- 1.0 mL kg-1 min-1) was significantly (P < 0.01) higher than that in the diabetic rats given saline (6.3 +/- 0.7 mL kg-1 min-1) or a randomly scrambled C-peptide (7.8 +/- 1.3 mL kg-1 min-1) at low-dose insulin infusion but not at the high-dose insulin infusion. Glucose 32-39 CD59 molecule (CD59 blood group) Homo sapiens 221-226 8621747-4 1996 The fit of the integrated symmetric Michaelis-Menten model to the time course of relative glucose signals yielded an estimated plasma glucose concentration for half maximal transport, Kt, of 4.8 +/- 2.4 mM (mean +/- SD), a maximal transport rate, Tmax, of 0.80 +/- 0.45 micromol g-1 min-1, and a cerebral metabolic glucose consumption rate (CMR)glc of 0.32 +/- 0.16 micromol g-1 min-1. Glucose 134-141 CD59 molecule (CD59 blood group) Homo sapiens 379-384 8621747-5 1996 Assuming cerebral glucose concentration to be 1.0 micromol/g at euglycemia as measured by 13CMR, the fit of the same model to the time course of brain glucose concentrations resulted in Kt = 3.9 +/- 0.82 mM, Tmax = 1.16 +/- 0.29 micromol g-1 min-1, and CMRglc = 0.35 +/- 0.10 micromol g-1 min-1. Glucose 18-25 CD59 molecule (CD59 blood group) Homo sapiens 242-247 8621747-5 1996 Assuming cerebral glucose concentration to be 1.0 micromol/g at euglycemia as measured by 13CMR, the fit of the same model to the time course of brain glucose concentrations resulted in Kt = 3.9 +/- 0.82 mM, Tmax = 1.16 +/- 0.29 micromol g-1 min-1, and CMRglc = 0.35 +/- 0.10 micromol g-1 min-1. Glucose 18-25 CD59 molecule (CD59 blood group) Homo sapiens 289-294 8621747-5 1996 Assuming cerebral glucose concentration to be 1.0 micromol/g at euglycemia as measured by 13CMR, the fit of the same model to the time course of brain glucose concentrations resulted in Kt = 3.9 +/- 0.82 mM, Tmax = 1.16 +/- 0.29 micromol g-1 min-1, and CMRglc = 0.35 +/- 0.10 micromol g-1 min-1. Glucose 151-158 CD59 molecule (CD59 blood group) Homo sapiens 242-247 8621747-5 1996 Assuming cerebral glucose concentration to be 1.0 micromol/g at euglycemia as measured by 13CMR, the fit of the same model to the time course of brain glucose concentrations resulted in Kt = 3.9 +/- 0.82 mM, Tmax = 1.16 +/- 0.29 micromol g-1 min-1, and CMRglc = 0.35 +/- 0.10 micromol g-1 min-1. Glucose 151-158 CD59 molecule (CD59 blood group) Homo sapiens 289-294 8623155-3 1996 Insulin-stimulated glucose disposal was reduced by 33% in kidney transplant patients compared with healthy controls (33.8 +/- 4.2 vs. 50.5 +/- 2.7 mumol (kg LBM)-1 min-1; P<0.01), primarily due to a decrease in nonoxidative glucose metabolism (14.2 +/- 3.3 vs. 32.3 +/- 2.7 mumol (kg LBM)-1 min-1; P<0.001). Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 164-169 8623155-3 1996 Insulin-stimulated glucose disposal was reduced by 33% in kidney transplant patients compared with healthy controls (33.8 +/- 4.2 vs. 50.5 +/- 2.7 mumol (kg LBM)-1 min-1; P<0.01), primarily due to a decrease in nonoxidative glucose metabolism (14.2 +/- 3.3 vs. 32.3 +/- 2.7 mumol (kg LBM)-1 min-1; P<0.001). Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 294-299 8593934-6 1996 Whole-body glucose uptake was 58% decreased in patients with NIDDM (20 +/- 3 micromol x kg body wt-1 x min-1) compared with normal subjects (47 +/- 4 micromol x kg body wt-1 x min-1, P < 0.001). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 103-108 8720607-9 1996 Hepatic glucose production at 1 mU.kg body weight-1.min-1 insulin-infusion rate was significantly higher in patients than in control subjects. Glucose 8-15 CD59 molecule (CD59 blood group) Homo sapiens 52-57 8593939-7 1996 Glucose disposal (1 mU x kg-1 x min-1) euglycemic insulin clamp with D-[3(-3)H]glucose) was higher in the normal glucose tolerance group compared with the impaired and diabetic groups (37.8 +/- 10.2 vs. 26.1 +/- 10.7 and 26.7 +/- 12.0 micromol x kg-1 x min-1; P < 0.05) despite similar BMIs in all three groups (28.8 +/- 3.7 kg/m2). Glucose 79-86 CD59 molecule (CD59 blood group) Homo sapiens 32-37 8593924-6 1995 Glucose metabolic clearance in the fasting state was 3.68 +2- 0.21 mg kg-1 min-1 before and 2.46 +/- 0.09 (n = 2.44 to 3.46 ml kg-1 min-1) after surgery. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 75-80 8593924-6 1995 Glucose metabolic clearance in the fasting state was 3.68 +2- 0.21 mg kg-1 min-1 before and 2.46 +/- 0.09 (n = 2.44 to 3.46 ml kg-1 min-1) after surgery. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 132-137 8750221-6 1995 Glucose production was lower (1.7 +/- 0.4 vs 0.5 +/- 0.4 mg kg-1 min-1, p < 0.05), and utilization was similar at the end of the matched-insulinaemia IV and IP clamps, respectively. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 65-70 8750221-7 1995 By contrast, glucose production was higher (1.7 +/- 0.5 IV vs 2.7 +/- 0.3 IP mg kg-1 min-1, p < 0.01) and glucose utilization lower (4.4 +/- 1.0 IV vs 3.3 +/- 0.2 IP mg kg-1 min-1, p < 0.05) with IP delivery at the end of the matched-dose clamps. Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 85-90 8750221-7 1995 By contrast, glucose production was higher (1.7 +/- 0.5 IV vs 2.7 +/- 0.3 IP mg kg-1 min-1, p < 0.01) and glucose utilization lower (4.4 +/- 1.0 IV vs 3.3 +/- 0.2 IP mg kg-1 min-1, p < 0.05) with IP delivery at the end of the matched-dose clamps. Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 177-182 8593934-6 1996 Whole-body glucose uptake was 58% decreased in patients with NIDDM (20 +/- 3 micromol x kg body wt-1 x min-1) compared with normal subjects (47 +/- 4 micromol x kg body wt-1 x min-1, P < 0.001). Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 176-181 8582132-8 1995 Infusion of GH at 12 mU kg-1 min-1 induced a less pronounced insulin resistance both with regards to maximal effect (glucose infusion rate C - GH 1.4 +/- 0.5 mg kg-1 min-1, p < 0.05) and duration (3 h). Glucose 117-124 CD59 molecule (CD59 blood group) Homo sapiens 29-34 8588954-6 1995 The transport systems obeyed Michaelis-Menten kinetics, with the kinetic parameters of the glucose transport system (Km = 2.5mM, Vmax = 7.7 nmol min-1 mg-1 protein) suggesting a higher proportion of PT cells originating from the S1-S2 segment of the nephron. Glucose 91-98 CD59 molecule (CD59 blood group) Homo sapiens 145-155 7593645-6 1995 In the basal postabsorptive state, there was small but significant net output of glucose by the kidney (66 +/- 22 mumol.min-1, P = 0.016). Glucose 81-88 CD59 molecule (CD59 blood group) Homo sapiens 120-125 7593645-7 1995 However, since renal glucose fractional extraction averaged 2.9 +/- 0.3%, there was considerable renal glucose uptake (2.3 +/- 0.2 mumol.kg-1.min-1) which accounted for 20.2 +/- 1.7% of systemic glucose disposal (11.4 +/- 0.5 mumol.kg-1.min-1). Glucose 103-110 CD59 molecule (CD59 blood group) Homo sapiens 142-147 7593645-7 1995 However, since renal glucose fractional extraction averaged 2.9 +/- 0.3%, there was considerable renal glucose uptake (2.3 +/- 0.2 mumol.kg-1.min-1) which accounted for 20.2 +/- 1.7% of systemic glucose disposal (11.4 +/- 0.5 mumol.kg-1.min-1). Glucose 103-110 CD59 molecule (CD59 blood group) Homo sapiens 237-242 7593645-7 1995 However, since renal glucose fractional extraction averaged 2.9 +/- 0.3%, there was considerable renal glucose uptake (2.3 +/- 0.2 mumol.kg-1.min-1) which accounted for 20.2 +/- 1.7% of systemic glucose disposal (11.4 +/- 0.5 mumol.kg-1.min-1). Glucose 103-110 CD59 molecule (CD59 blood group) Homo sapiens 142-147 7593645-7 1995 However, since renal glucose fractional extraction averaged 2.9 +/- 0.3%, there was considerable renal glucose uptake (2.3 +/- 0.2 mumol.kg-1.min-1) which accounted for 20.2 +/- 1.7% of systemic glucose disposal (11.4 +/- 0.5 mumol.kg-1.min-1). Glucose 103-110 CD59 molecule (CD59 blood group) Homo sapiens 237-242 7593645-8 1995 Renal glucose release (3.2 +/- 0.2 mumol.kg-1.min-1) accounted for 27.8 +/- 2.1% of systemic glucose appearance (11.4 +/- 0.5 mumol.kg-1.min-1). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 46-51 7593645-8 1995 Renal glucose release (3.2 +/- 0.2 mumol.kg-1.min-1) accounted for 27.8 +/- 2.1% of systemic glucose appearance (11.4 +/- 0.5 mumol.kg-1.min-1). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 137-142 8690177-4 1995 During euglycaemic, hyperinsulinaemic clamp (2 mU x kg-1 x min-1) in combination with indirect calorimetry, a 35% (p=0.005) increase in whole-body insulin-stimulated glucose disposal rate, predominantly due to an increased non-oxidative glucose metabolism (p=0.02) was demonstrated in teh gliclazide-treated patients when compared to pre-treatment values. Glucose 166-173 CD59 molecule (CD59 blood group) Homo sapiens 59-64 7820974-6 1994 The glucose-induced thermogenesis in the 120 min following the glucose load was significantly reduced by beta-adrenergic inhibition with approximately 50% from 63.9 +/- 5.8 kJ 120 min-1 (mean +/- SE) to 27.8 +/- 9.8 kJ 120 min-1 (P < 0.01). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 180-185 7485491-4 1995 Throughout the first period they received a continuous infusion of glucose (2 mg.kg-1.min-1) and amino acids. Glucose 67-74 CD59 molecule (CD59 blood group) Homo sapiens 86-91 7656918-4 1995 During the IGF-I infusion glucose appearance rate (Ra) decreased from 1.79 +/- 0.13 at baseline (150-180 min) to 0.35 +/- 0.26 mg kg-1 min-1 (P < 0.01) at 360 min, and glucose utilization rate (Rd) increased from 1.79 +/- 0.28 to 4.17 +/- 0.84 mg kg-1 min-1 (P < 0.01). Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 135-140 7656918-6 1995 During the insulin infusion glucose Ra decreased from 1.89 +/- 0.13 to 0.34 +/- 0.33 mg kg-1 min-1 (P < 0.01) and FFA from 0.546 mmol l-1 to 0.198 mmol l-1 (P < 0.01), glucose Rd increased from 1.89 +/- 0.18 to 5.41 +/- 1.47 mg kg-1 min-1 (P < 0.01) and there were no significant changes in the cardiovascular variables. Glucose 28-35 CD59 molecule (CD59 blood group) Homo sapiens 93-98 7758258-3 1995 The insulin sensitivity was assessed by the insulin (0.4 mU kg-1 min-1)-glucose/(4.5 mg kg-1 min-1)-infusion test (IGIT). Glucose 72-79 CD59 molecule (CD59 blood group) Homo sapiens 65-70 7729444-6 1995 After 90 min of cycling the rate of appearance of glucose increased significantly from means of 2.0 (SD 0.2) to 2.65 (SD 0.50) mg.kg-1.min-1 with unchanged blood concentrations of glucose and lactate. Glucose 50-57 CD59 molecule (CD59 blood group) Homo sapiens 135-140 7489026-7 1995 Glucose MCR increased from a mean baseline value of 3.0 +/- 1.6 to 6.7 +/- 3.9 ml kg-1 min-1 at post GBO (P) (P < 0.02). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 87-92 7820974-6 1994 The glucose-induced thermogenesis in the 120 min following the glucose load was significantly reduced by beta-adrenergic inhibition with approximately 50% from 63.9 +/- 5.8 kJ 120 min-1 (mean +/- SE) to 27.8 +/- 9.8 kJ 120 min-1 (P < 0.01). Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 223-228 7820974-8 1994 The integrated glucose-induced forearm oxygen uptake in the period 60-120 min following the glucose load was significantly reduced after beta-adrenergic inhibition from 103 +/- 28 mumol 100 g-1 60 min-1 to 29 +/- 29 mumol 100 g-1 60 min-1 (P < 0.05). Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 197-202 7820974-8 1994 The integrated glucose-induced forearm oxygen uptake in the period 60-120 min following the glucose load was significantly reduced after beta-adrenergic inhibition from 103 +/- 28 mumol 100 g-1 60 min-1 to 29 +/- 29 mumol 100 g-1 60 min-1 (P < 0.05). Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 233-238 7820974-8 1994 The integrated glucose-induced forearm oxygen uptake in the period 60-120 min following the glucose load was significantly reduced after beta-adrenergic inhibition from 103 +/- 28 mumol 100 g-1 60 min-1 to 29 +/- 29 mumol 100 g-1 60 min-1 (P < 0.05). Glucose 92-99 CD59 molecule (CD59 blood group) Homo sapiens 197-202 7820974-8 1994 The integrated glucose-induced forearm oxygen uptake in the period 60-120 min following the glucose load was significantly reduced after beta-adrenergic inhibition from 103 +/- 28 mumol 100 g-1 60 min-1 to 29 +/- 29 mumol 100 g-1 60 min-1 (P < 0.05). Glucose 92-99 CD59 molecule (CD59 blood group) Homo sapiens 233-238 8000156-7 1994 Physiological changes of lipolysis rates after 48 h of fasting followed by infusion of 4 mg.kg-1 body wt.min-1 glucose could also be adequately studied in one subject. Glucose 111-118 CD59 molecule (CD59 blood group) Homo sapiens 105-110 7815676-5 1994 Nonetheless, glucose oxidation decreased in the LCT group (from 6.42 +/- 1.04 to 2.31 +/- 0.85 mumol/kg.min-1, p < .001) and in the MCT/LCT group (from 7.62 +/- 1.50 to 5.50 +/- 0.76 mumol/kg.min-1, p < .01) but not in the control group. Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 104-109 7815676-5 1994 Nonetheless, glucose oxidation decreased in the LCT group (from 6.42 +/- 1.04 to 2.31 +/- 0.85 mumol/kg.min-1, p < .001) and in the MCT/LCT group (from 7.62 +/- 1.50 to 5.50 +/- 0.76 mumol/kg.min-1, p < .01) but not in the control group. Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 195-200 8000156-8 1994 Fast-induced elevated glycerol turnover at 7.56 mumol.kg-1 body wt.min-1, was substantially suppressed to 1.13 mumol.kg-1 body wt.min-1, when glucose was administered. Glucose 142-149 CD59 molecule (CD59 blood group) Homo sapiens 67-72 8000156-8 1994 Fast-induced elevated glycerol turnover at 7.56 mumol.kg-1 body wt.min-1, was substantially suppressed to 1.13 mumol.kg-1 body wt.min-1, when glucose was administered. Glucose 142-149 CD59 molecule (CD59 blood group) Homo sapiens 130-135 8033534-2 1994 Computing disappearance rates of glucose from its infused amounts necessary to maintain euglycaemia during 65 h after the insulin injection in analogy to experimental hyperinsulinaemic euglycaemic clamp examinations, a glucose consumption of 55.6 mumol kg-1 min-1 was found at peak serum insulin concentrations of about 14,400 pmol l-1. Glucose 33-40 CD59 molecule (CD59 blood group) Homo sapiens 258-263 8026143-5 1994 Glucose cycling was increased by 111% in NIDDM patients (118 +/- 18 mumole min-1 vs. 56 +/- 11 in controls, P < 0.05) and was positively correlated with plasma glucose concentration (r = 0.831, P < 0.001) and with non-oxidative glucose disposal (r = 0.714, P < 0.01). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 75-80 8306556-7 1994 Pretreatment glucose turnover rates [3.37 (2.57-4.16) mg min-1 kg-1] were comparable with those found in a previously reported study of non-pregnant severely ill patients [3.22 (2.12-4.82) mg min-1 kg-1, n = 11] and correlated significantly with the admission parasitaemia (P < 0.025). Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 57-67 8175515-3 1994 Plasma glucose levels were similar among all groups at all times during the trials; however, the glucose rates of appearance (Ra) at rest in CS (1.96 +/- 0.14 mg.kg-1 x min-1) and AS (2.02 +/- 0.14) were higher than in NS (1.41 +/- 0.15, P < 0.05). Glucose 97-104 CD59 molecule (CD59 blood group) Homo sapiens 169-174 8063042-3 1994 Insulin stimulated glucose uptake was decreased in the diabetic subjects (19.8 +/- 3.0 mumol.kg LBM-1.min-1, both p < 0.001) compared with control subjects (44.1 +/- 2.5 mumol.kg LBM-1.min-1) and relatives (39.9 +/- 3.3 mumol.kg LBM-1.min-1). Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 102-107 8063042-3 1994 Insulin stimulated glucose uptake was decreased in the diabetic subjects (19.8 +/- 3.0 mumol.kg LBM-1.min-1, both p < 0.001) compared with control subjects (44.1 +/- 2.5 mumol.kg LBM-1.min-1) and relatives (39.9 +/- 3.3 mumol.kg LBM-1.min-1). Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 188-193 8063042-3 1994 Insulin stimulated glucose uptake was decreased in the diabetic subjects (19.8 +/- 3.0 mumol.kg LBM-1.min-1, both p < 0.001) compared with control subjects (44.1 +/- 2.5 mumol.kg LBM-1.min-1) and relatives (39.9 +/- 3.3 mumol.kg LBM-1.min-1). Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 188-193 8121298-2 1994 In the present study, 10 patients suffering from congestive heart failure and 10 healthy age- and body mass index-matched subjects were submitted to a hyperinsulinemic (insulin infusion rate, 0.5 mU/kg.min-1) glucose clamp, while simultaneous D-3H-glucose infusion and indirect calorimetry allowed for determination of glucose turnover parameters and substrate oxidation, respectively. Glucose 209-216 CD59 molecule (CD59 blood group) Homo sapiens 202-207 8033534-3 1994 The insulin-induced glucose dynamics resemble closely those seen in healthy persons and Type 1 diabetic subjects during a 10 mU kg-1 min-1 euglycaemic clamp. Glucose 20-27 CD59 molecule (CD59 blood group) Homo sapiens 133-138 8128887-5 1993 The rate of insulin-stimulated glucose uptake was increased in the trained subjects (17.34 +/- 0.53 vs. 13.53 +/- 0.79 mg kg-1 min-1, P < 0.01). Glucose 31-38 CD59 molecule (CD59 blood group) Homo sapiens 127-132 8279537-4 1993 Glucose rate of appearance (Ra) declined equivalently in the 49 pmol.kg-1.min-1 IGF-I and insulin clamps but remained at basal levels during the 33 pmol.kg-1 x min-1 IGF-I infusions. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 74-79 8279537-4 1993 Glucose rate of appearance (Ra) declined equivalently in the 49 pmol.kg-1.min-1 IGF-I and insulin clamps but remained at basal levels during the 33 pmol.kg-1 x min-1 IGF-I infusions. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 160-165 8279537-5 1993 In contrast, Rd of glucose was increased by 176% in the 49 pmol.kg-1 x min-1 IGF-I and 78% in the 33 pmol.kg-1 x min-1 IGF-I infusions. Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 71-76 8279537-5 1993 In contrast, Rd of glucose was increased by 176% in the 49 pmol.kg-1 x min-1 IGF-I and 78% in the 33 pmol.kg-1 x min-1 IGF-I infusions. Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 113-118 8287659-6 1993 Indomethacin administration resulted in an increase in glucose production from 10.9 (SEM 0.3) mumol min-1 kg-1 to a maximum of 16.5 (SEM 1.6) mumol min-1 kg-1 (P < 0.05) within approximately 1 h, whereas in the control experiment glucose production declined gradually (P < 0.01) (P < 0.05 indomethacin versus control). Glucose 55-62 CD59 molecule (CD59 blood group) Homo sapiens 100-110 8306591-6 1993 Inhibition of NEFA metabolism was associated with increased insulin-stimulated glucose uptake (from 3.56 +/- 0.28 to 5.14 +/- 0.67 mumol kg-1 min-1, p < 0.05), mainly due to stimulation of non-oxidative glucose disposal (from 1.74 +/- 0.23 to 3.03 +/- 0.53 mumol kg-1 min-1, p < 0.05). Glucose 79-86 CD59 molecule (CD59 blood group) Homo sapiens 142-147 8306591-6 1993 Inhibition of NEFA metabolism was associated with increased insulin-stimulated glucose uptake (from 3.56 +/- 0.28 to 5.14 +/- 0.67 mumol kg-1 min-1, p < 0.05), mainly due to stimulation of non-oxidative glucose disposal (from 1.74 +/- 0.23 to 3.03 +/- 0.53 mumol kg-1 min-1, p < 0.05). Glucose 79-86 CD59 molecule (CD59 blood group) Homo sapiens 271-276 8108197-7 1993 The rate of appearance of glucose was lower in IDM infants studied during the first 6 h after birth (IDM 19.62 +/- 2.14 mumol/kg.min-1, normal infants 24.03 +/- 4.05 mumol/kg.min-1, p = 0.01). Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 129-134 8108197-7 1993 The rate of appearance of glucose was lower in IDM infants studied during the first 6 h after birth (IDM 19.62 +/- 2.14 mumol/kg.min-1, normal infants 24.03 +/- 4.05 mumol/kg.min-1, p = 0.01). Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 175-180 8108197-9 1993 Rate of appearance of glucose was lower (not significantly) in SGA infants (17.7 +/- 3.3 mumol/kg.min-1) as compared with normal infants. Glucose 22-29 CD59 molecule (CD59 blood group) Homo sapiens 98-103 8238493-6 1993 Hepatic glucose production was increased during the high-compared with low-dose infusions (9.5 +/- 1.1 vs. 5.1 +/- 2.2 mumol.kg-1 x min-1; P < 0.05). Glucose 8-15 CD59 molecule (CD59 blood group) Homo sapiens 132-137 8405705-13 1993 Plasma glucose rate of disappearance was significantly increased by alcohol intake in IDDM (13.72 +/- 0.82 vs. 11.84 +/- 0.53 mumol.kg-1 x min-1; P < 0.05). Glucose 7-14 CD59 molecule (CD59 blood group) Homo sapiens 139-144 8222508-9 1993 Whole-body insulin sensitivity was 10.5 +/- 2 mg of glucose min-1kg-1 after placebo, and 10.5 +/- 2.2 and 10.9 +/- 3.4 mg of glucose min-1kg-1 after low and high dose angiotensin II (not significant). Glucose 125-132 CD59 molecule (CD59 blood group) Homo sapiens 133-142 8214044-3 1993 Addition of angiotensin II increased whole body glucose uptake by 15% (9.2 +/- 0.5 vs. 10.8 +/- 0.8 mg.kg-1 x min-1; P = 0.011), and glucose oxidation (determined by indirect calorimetry) by 25% (4.0 +/- 0.3 vs. 4.9 +/- 0.4 mg.kg-1 x min-1; P < 0.05) over insulin alone. Glucose 48-55 CD59 molecule (CD59 blood group) Homo sapiens 110-115 8378116-4 1993 In 13 of 16 patients, the glucose production rate exceeded 1.0 mg.kg-1 x min-1. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 73-78 8412779-7 1993 Insulin-stimulated glucose uptake was assessed using the hyperinsulinemic euglycemic clamp technique and was increased post-metformin (3.8 +/- 0.6 v 3.1 +/- 0.7 mg.kg-1 x min-1, P < .05). Glucose 19-26 CD59 molecule (CD59 blood group) Homo sapiens 171-176 8378116-6 1993 The glucose oxidized (2.9 +/- 1.0 mg.kg-1 x min-1) was lower than the amount of glucose infused (p = 0.005) and was not different for appropriate-for-gestational-age and small-for-gestational-age infants. Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 44-49 8378116-9 1993 We conclude that preterm infants on the first day of life receiving a glucose infusion of 4.2 mg.kg-1 x min-1 continue to produce glucose. Glucose 70-77 CD59 molecule (CD59 blood group) Homo sapiens 104-109 8378116-9 1993 We conclude that preterm infants on the first day of life receiving a glucose infusion of 4.2 mg.kg-1 x min-1 continue to produce glucose. Glucose 130-137 CD59 molecule (CD59 blood group) Homo sapiens 104-109 8403788-9 1993 Hepatic glucose production was lower (1.5 +/- 0.4 versus 2.3 +/- 0.3 mg min-1 kg-1, P < 0.05) and peripheral glucose uptake was higher (7.4 +/- 1.0 versus 5.6 +/- 0.6 mg min-1 kg-1, P < 0.01) during infusion of the hormones compared with during hypoglycaemia. Glucose 8-15 CD59 molecule (CD59 blood group) Homo sapiens 72-82 8396523-7 1993 The glucose-induced thermogenesis in the 180 min following the glucose load was 93.6 +/- 9.9 kJ 180 min-1 before chemotherapy. Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 100-105 8396523-7 1993 The glucose-induced thermogenesis in the 180 min following the glucose load was 93.6 +/- 9.9 kJ 180 min-1 before chemotherapy. Glucose 63-70 CD59 molecule (CD59 blood group) Homo sapiens 100-105 8396523-9 1993 The glucose-induced thermogenesis was significantly reduced to 47.7 +/- 10.2 kJ 180 min-1 (P < 0.05) after chemotherapy. Glucose 4-11 CD59 molecule (CD59 blood group) Homo sapiens 84-89 8480681-2 1993 In control subjects (placebo-treated vs vitamin E-supplemented subjects, respectively) vitamin E reduced the area under the curve for glucose (344 +/- 21 vs 287 +/- 13 mmol.L-1 x min-1; P < 0.05) and increased total body glucose disposal (39.0 +/- 0.3 vs 47.6 +/- 0.4 mumol.kg lean body mass-1 x min-1; P < 0.05) and non-oxidative glucose metabolism (23.4 +/- 0.2 vs 30.8 +/- 0.3 mumol.kg lean body mass-1 x min-1; P < 0.05). Glucose 134-141 CD59 molecule (CD59 blood group) Homo sapiens 179-184 8508613-3 1993 The 5 mg glucose.kg ideal body weight.min-1 continuous infusion of glucose with model assessment (CIGMA) test was used to quantitate glucose tolerance, beta cell function, and insulin sensitivity. Glucose 67-74 CD59 molecule (CD59 blood group) Homo sapiens 38-43 8378116-5 1993 Infants born from mothers who had been receiving steroids antenatally had higher glucose production rates (2.3 +/- 1.1 mg.kg-1 x min-1) compared with infants from mothers who had not (1.1 +/- 0.8 mg.kg-1 x min-1, p = 0.036). Glucose 81-88 CD59 molecule (CD59 blood group) Homo sapiens 129-134 1587401-4 1992 Tests were preceded by identical fasts of 10-12 h. In nonobese subjects, glucose tolerance, expressed as the 10- to 16-min KG value (KGs), was much reduced in the evening (AM 2.98 +/- 0.45, PM 1.86 +/- 0.33 min-1, P less than 0.002). Glucose 73-80 CD59 molecule (CD59 blood group) Homo sapiens 207-212 8514702-7 1993 For days 1 and 3 combined, total integrated areas for the glucose and insulin response curves averaged 1,683 mumol.ml-1.240 min-1 and 21,450 microU.ml-1.240 min-1, respectively. Glucose 58-65 CD59 molecule (CD59 blood group) Homo sapiens 124-129 8514702-7 1993 For days 1 and 3 combined, total integrated areas for the glucose and insulin response curves averaged 1,683 mumol.ml-1.240 min-1 and 21,450 microU.ml-1.240 min-1, respectively. Glucose 58-65 CD59 molecule (CD59 blood group) Homo sapiens 157-162 8430789-4 1993 Basal endogenous glucose production increased during gestation [Ctl: P 2.74 +/- 0.23, E 2.62 +/- 0.38, and L 3.14 +/- 0.36; GDM: P 2.68 +/- 0.51, E 2.78 +/- 0.45, and L 2.98 +/- 0.48 mg.kg fat-free mass (FFM)-1 x min-1; P = 0.02], but there was resistance to suppression by insulin infusion (P = 0.03) in late gestation (GDM: 0.61 +/- 0.44 vs. Ctl: 0.16 +/- 0.17 mg.kg FFM-1 x min-1). Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 213-218 8430789-4 1993 Basal endogenous glucose production increased during gestation [Ctl: P 2.74 +/- 0.23, E 2.62 +/- 0.38, and L 3.14 +/- 0.36; GDM: P 2.68 +/- 0.51, E 2.78 +/- 0.45, and L 2.98 +/- 0.48 mg.kg fat-free mass (FFM)-1 x min-1; P = 0.02], but there was resistance to suppression by insulin infusion (P = 0.03) in late gestation (GDM: 0.61 +/- 0.44 vs. Ctl: 0.16 +/- 0.17 mg.kg FFM-1 x min-1). Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 377-382 8435988-2 1993 Glucose disposal (assessed by the euglycaemic insulin clamp technique) was significantly reduced in diabetic patients compared to control subjects (4.4 +/- 0.5 vs 6.4 +/- 0.5 mg kg-1 min-1, p < 0.05), and increased after 1 and 3 months of sulphonylurea therapy to 6.8 +/- 0.6 mg kg-1 min-1 (p = 0.01) and 6.3 +/- 0.7 mg kg-1 min-1 (p = 0.04), respectively. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 183-188 8435988-2 1993 Glucose disposal (assessed by the euglycaemic insulin clamp technique) was significantly reduced in diabetic patients compared to control subjects (4.4 +/- 0.5 vs 6.4 +/- 0.5 mg kg-1 min-1, p < 0.05), and increased after 1 and 3 months of sulphonylurea therapy to 6.8 +/- 0.6 mg kg-1 min-1 (p = 0.01) and 6.3 +/- 0.7 mg kg-1 min-1 (p = 0.04), respectively. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 287-292 8435988-2 1993 Glucose disposal (assessed by the euglycaemic insulin clamp technique) was significantly reduced in diabetic patients compared to control subjects (4.4 +/- 0.5 vs 6.4 +/- 0.5 mg kg-1 min-1, p < 0.05), and increased after 1 and 3 months of sulphonylurea therapy to 6.8 +/- 0.6 mg kg-1 min-1 (p = 0.01) and 6.3 +/- 0.7 mg kg-1 min-1 (p = 0.04), respectively. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 287-292 8504885-7 1993 The mean glucose infusion rate during the clamp was low in the diabetic girls (2.29 +/- 1.35 mg kg-1 min-1), confirming the existence of insulin resistance. Glucose 9-16 CD59 molecule (CD59 blood group) Homo sapiens 101-106 1443116-8 1992 Local forearm glucose uptake was 0.160 +/- 0.105 mumol.100 g-1 x min-1 and increased to 0.586 +/- 0.445 and 0.760 +/- 0.534 mumol.100 g-1 x min-1 (P < 0.025). Glucose 14-21 CD59 molecule (CD59 blood group) Homo sapiens 65-70 1443116-8 1992 Local forearm glucose uptake was 0.160 +/- 0.105 mumol.100 g-1 x min-1 and increased to 0.586 +/- 0.445 and 0.760 +/- 0.534 mumol.100 g-1 x min-1 (P < 0.025). Glucose 14-21 CD59 molecule (CD59 blood group) Homo sapiens 140-145 1449039-6 1992 Total glucose uptake was impaired in the insulin-resistant subjects with impaired first-phase insulin secretion compared to controls (18.8 (13.2-22.2) vs 34.8 (24.3-62.1) mumol.kg-1 x min-1; p < 0.01). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 184-189 8480475-6 1993 Insulin-stimulated (2 mU.kg-1 x min-1) glucose disposal rate tended to be increased (18%, p = 0.10) after dexfenfluramine. Glucose 39-46 CD59 molecule (CD59 blood group) Homo sapiens 32-37 8445040-7 1993 Again, rates of glucose metabolism were higher during IGF-1 infusion (11.8 +/- 1.2 vs 8.9 +/- 0.8 mg kg-1 min-1, p < 0.01). Glucose 16-23 CD59 molecule (CD59 blood group) Homo sapiens 106-111 8504458-2 1993 Keeping the fluorescence intensities at low levels, regular oscillations of [Ca2+]i with a frequency of 0.2-0.5 min-1 could be recorded for more than 60 min in glucose-stimulated cells. Glucose 160-167 CD59 molecule (CD59 blood group) Homo sapiens 112-117 8458523-4 1993 Endogenous glucose production ([6-3H]glucose) was greater in diabetic than control subjects in the post-absorptive state (15.6 +/- 1.5 vs 11.3 +/- 0.4 mumol.kg-1 x min-1, p < 0.05) and during the 0.4 mU insulin infusion (10.1 +/- 1.3 vs 5.2 +/- 0.3 mumol.kg-1 x min-1, p < 0.01) indicating hepatic insulin resistance. Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 164-169 8458523-4 1993 Endogenous glucose production ([6-3H]glucose) was greater in diabetic than control subjects in the post-absorptive state (15.6 +/- 1.5 vs 11.3 +/- 0.4 mumol.kg-1 x min-1, p < 0.05) and during the 0.4 mU insulin infusion (10.1 +/- 1.3 vs 5.2 +/- 0.3 mumol.kg-1 x min-1, p < 0.01) indicating hepatic insulin resistance. Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 265-270 8458523-5 1993 Glucose/glucose 6-phosphate cycling was significantly greater in diabetic than in control subjects in the post-absorptive state (2.6 +/- 0.4 vs 1.6 +/- 0.2 mumol.kg-1 x min-1, p < 0.05) but not during the 0.4 mU insulin infusion (2.0 +/- 0.4 vs 2.0 +/- 0.3 mumol.kg-1 x min-1). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 169-174 8458523-5 1993 Glucose/glucose 6-phosphate cycling was significantly greater in diabetic than in control subjects in the post-absorptive state (2.6 +/- 0.4 vs 1.6 +/- 0.2 mumol.kg-1 x min-1, p < 0.05) but not during the 0.4 mU insulin infusion (2.0 +/- 0.4 vs 2.0 +/- 0.3 mumol.kg-1 x min-1). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 273-278 1478365-8 1992 Stimulation of glucose disposal by insulin was reduced in hypertriglyceridaemic vs normotriglyceridaemic patients (27.0 +/- 1.3 vs 31.9 +/- 1.6 mumol.kg-1 x min-1; p < 0.05) primarily due to impaired glucose storage (9.8 +/- 1.0 vs 14.6 +/- 1.4 mumol.kg-1 x min-1; p < 0.01). Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 157-162 1478365-8 1992 Stimulation of glucose disposal by insulin was reduced in hypertriglyceridaemic vs normotriglyceridaemic patients (27.0 +/- 1.3 vs 31.9 +/- 1.6 mumol.kg-1 x min-1; p < 0.05) primarily due to impaired glucose storage (9.8 +/- 1.0 vs 14.6 +/- 1.4 mumol.kg-1 x min-1; p < 0.01). Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 261-266 1397716-6 1992 Basal HGO and fasting plasma glucose levels were lower (94.1 +/- 9.2 vs. 118.5 +/- 9.5 mg.m-2 x min-1, P = 0.01; and 8.3 +/- 1.2 vs. 9.8 +/- 1.2 mM; P < 0.001), respectively. Glucose 29-36 CD59 molecule (CD59 blood group) Homo sapiens 96-101 1587401-6 1992 The reduction in glucose tolerance in the normal-weight subjects was caused by diminished insulin sensitivity (parameter S1, AM 15.4 +/- 2.9, PM 10.2 +/- 1.9 x 10(-5) min-1/pM, P less than 0.01) and reduced beta-cell responsivity to glucose. Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 167-172 1499640-3 1992 Mean fasting hepatic glucose production was 14.2 +/- 0.8 mumol kg-1 min-1. Glucose 21-28 CD59 molecule (CD59 blood group) Homo sapiens 68-73 1734672-3 1992 Total glucose disposal during insulin clamp increased from 30.4 +/- 4.3 to 38.4 +/- 4.4 mumol.kg lean body mass (LBM)-1.min-1 (P less than 0.05), insulin-stimulated glucose oxidation from 14.3 +/- 4.6 to 19.1 +/- 1.4 mumol.kg LBM-1.min-1 (P less than 0.05), and non-oxidative glucose metabolism from 16.0 +/- 3.8 to 19.3 +/- 3.6 mumol.kg LBM-1.min-1 (NS). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 120-125 1734672-3 1992 Total glucose disposal during insulin clamp increased from 30.4 +/- 4.3 to 38.4 +/- 4.4 mumol.kg lean body mass (LBM)-1.min-1 (P less than 0.05), insulin-stimulated glucose oxidation from 14.3 +/- 4.6 to 19.1 +/- 1.4 mumol.kg LBM-1.min-1 (P less than 0.05), and non-oxidative glucose metabolism from 16.0 +/- 3.8 to 19.3 +/- 3.6 mumol.kg LBM-1.min-1 (NS). Glucose 165-172 CD59 molecule (CD59 blood group) Homo sapiens 232-237 1734672-3 1992 Total glucose disposal during insulin clamp increased from 30.4 +/- 4.3 to 38.4 +/- 4.4 mumol.kg lean body mass (LBM)-1.min-1 (P less than 0.05), insulin-stimulated glucose oxidation from 14.3 +/- 4.6 to 19.1 +/- 1.4 mumol.kg LBM-1.min-1 (P less than 0.05), and non-oxidative glucose metabolism from 16.0 +/- 3.8 to 19.3 +/- 3.6 mumol.kg LBM-1.min-1 (NS). Glucose 165-172 CD59 molecule (CD59 blood group) Homo sapiens 232-237 1734672-3 1992 Total glucose disposal during insulin clamp increased from 30.4 +/- 4.3 to 38.4 +/- 4.4 mumol.kg lean body mass (LBM)-1.min-1 (P less than 0.05), insulin-stimulated glucose oxidation from 14.3 +/- 4.6 to 19.1 +/- 1.4 mumol.kg LBM-1.min-1 (P less than 0.05), and non-oxidative glucose metabolism from 16.0 +/- 3.8 to 19.3 +/- 3.6 mumol.kg LBM-1.min-1 (NS). Glucose 165-172 CD59 molecule (CD59 blood group) Homo sapiens 232-237 1734672-3 1992 Total glucose disposal during insulin clamp increased from 30.4 +/- 4.3 to 38.4 +/- 4.4 mumol.kg lean body mass (LBM)-1.min-1 (P less than 0.05), insulin-stimulated glucose oxidation from 14.3 +/- 4.6 to 19.1 +/- 1.4 mumol.kg LBM-1.min-1 (P less than 0.05), and non-oxidative glucose metabolism from 16.0 +/- 3.8 to 19.3 +/- 3.6 mumol.kg LBM-1.min-1 (NS). Glucose 165-172 CD59 molecule (CD59 blood group) Homo sapiens 232-237 1936660-2 1991 The effect of 53 h of 2.2 mg glucose.kg ideal body weight-1.min-1 was examined in four normal male subjects. Glucose 29-36 CD59 molecule (CD59 blood group) Homo sapiens 60-65 1838062-6 1991 Basal hepatic glucose production was higher in subjects with Impaired Glucose Tolerance (6.3 +/- 0.4 vs 4.5 +/- 0.6 mol kg-1 min-1, p less than 0.02) and remained elevated during infusion (p less than 0.01). Glucose 14-21 CD59 molecule (CD59 blood group) Homo sapiens 125-130 1838062-7 1991 Glucose disposal per unit circulating insulin at the maximal infusion rate was approximately half in subjects with Impaired Glucose Tolerance (0.022 +/- 0.010 vs 0.047 +/- 0.017 ml kg-1 min-1 mU-1 l, p less than 0.01). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 186-191 1672795-5 1991 Steady-state glucose disposal during hyperglycemia averaged (+/- SE) 33.8 +/- 3.2 mumol.kg fat-free mass-1.min-1, and approximately 70% of the glucose disposal was accounted for by skeletal muscle. Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 107-112 2176947-8 1990 The plasma noradrenaline concentration was 74 and 230% and the blood glucose concentration was 21 and 36% higher than control values at 5 and 10 micrograms of dopamine min-1 kg-1, respectively (P less than 0.01). Glucose 69-76 CD59 molecule (CD59 blood group) Homo sapiens 168-178 2083480-5 1990 Net splanchnic glucose balance switched from a positive value (i.e. net uptake) of 5.06 +/- 2.56 mumol min-1 kg-1 with intravenous glucose alone (0-60 min) to a negative one (i.e. net output) of 12.50 +/- 2.44 mumol min-1 kg-1 during 4 h (60-300 min) of intravenous + oral glucose. Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 103-113 2083480-5 1990 Net splanchnic glucose balance switched from a positive value (i.e. net uptake) of 5.06 +/- 2.56 mumol min-1 kg-1 with intravenous glucose alone (0-60 min) to a negative one (i.e. net output) of 12.50 +/- 2.44 mumol min-1 kg-1 during 4 h (60-300 min) of intravenous + oral glucose. Glucose 15-22 CD59 molecule (CD59 blood group) Homo sapiens 216-226 2083480-6 1990 The mean rate of splanchnic glucose uptake was estimated to be 6.39 +/- 4.67 mumol min-1 kg-1 with intravenous glucose alone, and 8.83 +/- 4.28 mumol min-1 kg-1 with intravenous + oral glucose. Glucose 28-35 CD59 molecule (CD59 blood group) Homo sapiens 83-93 2200838-5 1990 Both glucose uptake (5.0 +/- 0.6 vs 6.2 +/- 0.7 mg kg-1 min-1; P less than 0.05) and tissue sensitivity (M/I; 0.08 +/- 0.02 vs. 0.1 +/- 0.02 mg kg-1 min-1/mU l-1; P less than 0.05) increased between the first and second euglycaemic clamp (40 mU m-2 min-1). Glucose 5-12 CD59 molecule (CD59 blood group) Homo sapiens 56-61 2076800-6 1990 Negative endogenous glucose production rates were observed both at 90-120 min (-8.8 +/- 1.6 mumol.kg-1min-1) and at 210-240 min (-8.5 +/- 1.4 mumol.kg-1min-1) implying a persistent underestimate in isotopically determined glucose appearance rate. Glucose 20-27 CD59 molecule (CD59 blood group) Homo sapiens 102-107 2148133-4 1990 In vivo peripheral insulin sensitivity (euglycaemic clamp with insulin infusion of 40, 160, and 600 mU m-2 min-1, respectively) was significantly improved (glucose requirement: to 4.7 +/- 1.0 from 3.0 +/- 0.6 mg kg-1 min-1, p less than 0.05 at first insulin level; to 10.8 +/- 0.5 from 9.3 +/- 0.7 mg kg-1 min-1, p less than 0.01 at second level; to 13.3 +/- 0.6 from 11.8 +/- 0.8 mg kg-1 min-1, p less than 0.025 at third level). Glucose 156-163 CD59 molecule (CD59 blood group) Homo sapiens 107-112 2148133-5 1990 Basal hepatic glucose production was also significantly reduced (from 4.3 +/- 0.4 to 3.3 +/- 0.3 mg kg-1 min-1, p less than 0.05), and residual glucose production further suppressed after insulin supplement (from 1.1 +/- 0.4 to 0.3 +/- 0.2 mg kg-1 min-1 after 120 min at 100 mU l-1 plasma insulin, p less than 0.05). Glucose 14-21 CD59 molecule (CD59 blood group) Homo sapiens 105-110 2272963-3 1990 The maximal rate of glucose disposal attained during the clamp averaged 15.7 +/- 1.0 mg.kg lean body mass-1.min-1 after exercise vs. a control value of 15.4 mg.kg lean body mass-1.min-1. Glucose 20-27 CD59 molecule (CD59 blood group) Homo sapiens 108-113 2142039-6 1990 Glucose requirement during the clamp was decreased in the Type 2 diabetic patients at presentation (2.2 +/- 0.7 vs 7.3 +/- 0.6 mg kg-1 min-1, p less than 0.001), and despite improvement following dietary treatment to 3.3 +/- 0.6 mg kg-1 min-1 (p less than 0.01) remained lower than in the control subjects (p less than 0.001). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 135-140 2142039-6 1990 Glucose requirement during the clamp was decreased in the Type 2 diabetic patients at presentation (2.2 +/- 0.7 vs 7.3 +/- 0.6 mg kg-1 min-1, p less than 0.001), and despite improvement following dietary treatment to 3.3 +/- 0.6 mg kg-1 min-1 (p less than 0.01) remained lower than in the control subjects (p less than 0.001). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 237-242 2110608-5 1990 After 16-hour fasting net glucose oxidation was 0.59 +/- 0.17 mg x kg-1 x min-1 and glucose tissue uptake 2.34 +/- 0.12 mg x kg-1 x min-1. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 74-79 2176947-14 1990 It increases the blood glucose concentration and the circulating noradrenaline level at an infusion rate of 5 micrograms min-1 kg-1. Glucose 23-30 CD59 molecule (CD59 blood group) Homo sapiens 121-131 2137755-5 1990 Insulin-mediated glucose disposal rose from 2.5 (1.5-8.0) (median (range] to 4.2 (2.3-8.4) mg kg-1 min-1 in the glipizide group (n = 9, p less than 0.01), but did not change in the placebo group. Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 99-104 2137065-4 1990 Glucose disposal rates were 2.5 +/- 0.3 (mean +/- SE) mg kg-1 min-1 during the follicular phase and 3.2 +/- 0.3 mg kg-1 min-1 in the luteal phase with low dose insulin, and 5.9 +/- 0.4 and 6.4 +/- 0.6 mg kg-1 min-1, respectively, with high dose insulin. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 62-67 1969348-4 1990 The steady-state glucose infusion rate necessary to maintain a stable plasma glucose concentration of 4.4-5.0 mmol l-1 was significantly (P less than or equal to 0.001) higher in insulinoma patients (2.5 +/- 0.6 mg kg-1 min-1) than in pancreas resected patients (0.6 +/- 0.2 mg kg-1 min-1), or in control subjects (0.5 +/- 0.1 mg kg-1 min-1). Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 220-225 1969348-4 1990 The steady-state glucose infusion rate necessary to maintain a stable plasma glucose concentration of 4.4-5.0 mmol l-1 was significantly (P less than or equal to 0.001) higher in insulinoma patients (2.5 +/- 0.6 mg kg-1 min-1) than in pancreas resected patients (0.6 +/- 0.2 mg kg-1 min-1), or in control subjects (0.5 +/- 0.1 mg kg-1 min-1). Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 283-288 1969348-4 1990 The steady-state glucose infusion rate necessary to maintain a stable plasma glucose concentration of 4.4-5.0 mmol l-1 was significantly (P less than or equal to 0.001) higher in insulinoma patients (2.5 +/- 0.6 mg kg-1 min-1) than in pancreas resected patients (0.6 +/- 0.2 mg kg-1 min-1), or in control subjects (0.5 +/- 0.1 mg kg-1 min-1). Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 283-288 2137065-4 1990 Glucose disposal rates were 2.5 +/- 0.3 (mean +/- SE) mg kg-1 min-1 during the follicular phase and 3.2 +/- 0.3 mg kg-1 min-1 in the luteal phase with low dose insulin, and 5.9 +/- 0.4 and 6.4 +/- 0.6 mg kg-1 min-1, respectively, with high dose insulin. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 120-125 2137065-4 1990 Glucose disposal rates were 2.5 +/- 0.3 (mean +/- SE) mg kg-1 min-1 during the follicular phase and 3.2 +/- 0.3 mg kg-1 min-1 in the luteal phase with low dose insulin, and 5.9 +/- 0.4 and 6.4 +/- 0.6 mg kg-1 min-1, respectively, with high dose insulin. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 120-125 2912154-8 1989 Conversely, zinc (0.9 mM) also enhanced the absorption of glucose, which was increased from 293 +/- 43 to 447 +/- 27 microM.min-1.40 cm-1 (P less than 0.05). Glucose 58-65 CD59 molecule (CD59 blood group) Homo sapiens 124-129 2210020-4 1990 Their basal glucose productions, measured by [6,6(-2)H] glucose constant infusion, were 3.3, 2.6 and 3.4 mg kg-1 min-1, respectively; they did not correlate with fasting plasma glucose. Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 113-118 2210020-5 1990 Glucose production in response to a 2 mg kg-1 min- unlabeled glucose infusion, was normally suppressed in L2, but was incompletely suppressed (by 1.5 mg kg-1 min-1) in L1 and L3. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 158-163 34524975-0 2021 Plasma glycated CD59 predicts postpartum glucose intolerance after gestational diabetes. Glucose 41-48 CD59 molecule (CD59 blood group) Homo sapiens 16-20 34524975-1 2021 AIMS: To assess whether in women with gestational diabetes mellitus (GDM), postpartum plasma glycated CD59 (pGCD59) levels predict conversion to glucose intolerance diagnosed with an oral glucose tolerance test (OGTT). Glucose 145-152 CD59 molecule (CD59 blood group) Homo sapiens 102-106 34524975-1 2021 AIMS: To assess whether in women with gestational diabetes mellitus (GDM), postpartum plasma glycated CD59 (pGCD59) levels predict conversion to glucose intolerance diagnosed with an oral glucose tolerance test (OGTT). Glucose 188-195 CD59 molecule (CD59 blood group) Homo sapiens 102-106 2500510-5 1989 With glucose loading, infants with bronchopulmonary dysplasia had a significant rise in basal oxygen consumption (7.91 +/- 0.91 ml.kg-1.min-1 to 9.65 +/- 1.35 ml.kg-1.min-1, p less than 0.05), basal carbon dioxide production (5.93 +/- 0.72 ml.kg-1.min-1 to 7.10 +/- 1.04 ml.kg-1.min-1), and resting energy expenditure (53.8 +/- 5.75 kcal.kg-1.24 hr-1 to 65.3 +/- 7.0 kcal.kg-1.24 hr-1, all p values less than 0.05). Glucose 5-12 CD59 molecule (CD59 blood group) Homo sapiens 136-141 2500510-5 1989 With glucose loading, infants with bronchopulmonary dysplasia had a significant rise in basal oxygen consumption (7.91 +/- 0.91 ml.kg-1.min-1 to 9.65 +/- 1.35 ml.kg-1.min-1, p less than 0.05), basal carbon dioxide production (5.93 +/- 0.72 ml.kg-1.min-1 to 7.10 +/- 1.04 ml.kg-1.min-1), and resting energy expenditure (53.8 +/- 5.75 kcal.kg-1.24 hr-1 to 65.3 +/- 7.0 kcal.kg-1.24 hr-1, all p values less than 0.05). Glucose 5-12 CD59 molecule (CD59 blood group) Homo sapiens 167-172 2500510-5 1989 With glucose loading, infants with bronchopulmonary dysplasia had a significant rise in basal oxygen consumption (7.91 +/- 0.91 ml.kg-1.min-1 to 9.65 +/- 1.35 ml.kg-1.min-1, p less than 0.05), basal carbon dioxide production (5.93 +/- 0.72 ml.kg-1.min-1 to 7.10 +/- 1.04 ml.kg-1.min-1), and resting energy expenditure (53.8 +/- 5.75 kcal.kg-1.24 hr-1 to 65.3 +/- 7.0 kcal.kg-1.24 hr-1, all p values less than 0.05). Glucose 5-12 CD59 molecule (CD59 blood group) Homo sapiens 167-172 2500510-5 1989 With glucose loading, infants with bronchopulmonary dysplasia had a significant rise in basal oxygen consumption (7.91 +/- 0.91 ml.kg-1.min-1 to 9.65 +/- 1.35 ml.kg-1.min-1, p less than 0.05), basal carbon dioxide production (5.93 +/- 0.72 ml.kg-1.min-1 to 7.10 +/- 1.04 ml.kg-1.min-1), and resting energy expenditure (53.8 +/- 5.75 kcal.kg-1.24 hr-1 to 65.3 +/- 7.0 kcal.kg-1.24 hr-1, all p values less than 0.05). Glucose 5-12 CD59 molecule (CD59 blood group) Homo sapiens 167-172 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 43-48 2646944-5 1989 There was a positive correlation before training between maximum O2 uptake (Vo2 max) and total body glucose disposal rate (M) at the 40 mU.m-2.min-1 insulin infusion (r = 0.69, P less than 0.02). Glucose 100-107 CD59 molecule (CD59 blood group) Homo sapiens 143-148 2976647-5 1988 Twelve diet-treated diabetic patients and 11 normal subjects were given a continuous low-dose glucose infusion for 60 min at a rate of 5 mg kg-1 ideal body weight min-1, after which the infusion was turned off and the plasma glucose level allowed to fall. Glucose 94-101 CD59 molecule (CD59 blood group) Homo sapiens 163-168 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 43-48 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 43-48 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-4 1988 During infusion of 3.9 mg glucose x kg-1 x min-1 glucose tissue uptake was 4.6 +/- 0.3 mg x kg-1 x min-1, glucose oxidation 0.5 +/- 0.2 mg x kg-1 x min-1, FFA concentration 377 +/- 52 mumol x L-1, and lipid oxidation 2.0 +/- 0.2 mumol x kg-1 x min-1. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 99-104 3054431-5 1988 During the euglycemic clamp glucose tissue uptake was 4.4 +/- 0.3 mg x kg-1 x min-1, glucose oxidation rose to 1.8 mg x kg-1 x min-1 (.001 less than P less than .01), FFA concentration dropped to 202 +/- 23 mumol x L-1 (P less than .001), and lipid oxidation to 1.2 +/- 0.2 mumol x kg-1 x min-1 (.001 less than P less than .01). Glucose 28-35 CD59 molecule (CD59 blood group) Homo sapiens 78-83 3054431-7 1988 It is concluded that in septic cancer-bearing patients glucose oxidation is inhibited during infusion of 3.9 mg glucose x kg-1 x min-1, even when expressed as percentage of glucose tissue uptake. Glucose 55-62 CD59 molecule (CD59 blood group) Homo sapiens 129-134 3054431-7 1988 It is concluded that in septic cancer-bearing patients glucose oxidation is inhibited during infusion of 3.9 mg glucose x kg-1 x min-1, even when expressed as percentage of glucose tissue uptake. Glucose 112-119 CD59 molecule (CD59 blood group) Homo sapiens 129-134 3054431-7 1988 It is concluded that in septic cancer-bearing patients glucose oxidation is inhibited during infusion of 3.9 mg glucose x kg-1 x min-1, even when expressed as percentage of glucose tissue uptake. Glucose 112-119 CD59 molecule (CD59 blood group) Homo sapiens 129-134 3242682-4 1988 A range of glucose production of 3.5-1.8 mg kg-1 min-1 was found when glucose infusion rates increased from 0.13 to 6 mg kg-1 min-1. Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 49-54 3242682-4 1988 A range of glucose production of 3.5-1.8 mg kg-1 min-1 was found when glucose infusion rates increased from 0.13 to 6 mg kg-1 min-1. Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 126-131 3242682-4 1988 A range of glucose production of 3.5-1.8 mg kg-1 min-1 was found when glucose infusion rates increased from 0.13 to 6 mg kg-1 min-1. Glucose 70-77 CD59 molecule (CD59 blood group) Homo sapiens 49-54 3242682-4 1988 A range of glucose production of 3.5-1.8 mg kg-1 min-1 was found when glucose infusion rates increased from 0.13 to 6 mg kg-1 min-1. Glucose 70-77 CD59 molecule (CD59 blood group) Homo sapiens 126-131 3138512-4 1988 The rate of glucose disappearance (RdG) increased from 2.41 +/- 0.40 at rest to 3.38 +/- 0.77 mg x kg-1 x min-1 during exercise, compared with the much larger rise in the rate of lactate appearance (RaL), which increased from 1.25 +/- 0.20 to 3.47 +/- 0.79 mg x kg-1 x min-1. Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 106-111 3147900-2 1988 Clamp glucose requirement (insulin, 0.1 U kg-1 h-1) was significantly lower in the older subjects (8.0 +/- 0.4 mg kg-1 min-1) than in younger subjects (10.5 +/- 0.6 mg kg-1 min-1, P less than 0.02). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 119-124 3138512-4 1988 The rate of glucose disappearance (RdG) increased from 2.41 +/- 0.40 at rest to 3.38 +/- 0.77 mg x kg-1 x min-1 during exercise, compared with the much larger rise in the rate of lactate appearance (RaL), which increased from 1.25 +/- 0.20 to 3.47 +/- 0.79 mg x kg-1 x min-1. Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 269-274 3138512-7 1988 From secondary labeling of lactate with glucose carbons, the rate of glucose conversion to lactate was estimated to be 0.65 +/- 0.16 mg x kg-1 x min-1 during exercise. Glucose 69-76 CD59 molecule (CD59 blood group) Homo sapiens 145-150 3552793-6 1987 The basal glucose disposal rate was 86 +/- 2 mg X m-2 X min-1 and did not increase significantly during the clamp studies. Glucose 10-17 CD59 molecule (CD59 blood group) Homo sapiens 56-61 2524341-6 1989 Glucose infusion requirements rose significantly during the exercise period from 2.8 +/- 0.5 mg kg-1 min-1 to a peak at 235 min of 11.1 +/- 1.2 mg kg-1 min-1 (p less than 0.001), compared with an increase on the control day from 2.0 +/- 0.6 to 2.5 +/- 0.6 mg kg-1 min-1 (NS) over the same period. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 101-106 2524341-6 1989 Glucose infusion requirements rose significantly during the exercise period from 2.8 +/- 0.5 mg kg-1 min-1 to a peak at 235 min of 11.1 +/- 1.2 mg kg-1 min-1 (p less than 0.001), compared with an increase on the control day from 2.0 +/- 0.6 to 2.5 +/- 0.6 mg kg-1 min-1 (NS) over the same period. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 152-157 2524341-6 1989 Glucose infusion requirements rose significantly during the exercise period from 2.8 +/- 0.5 mg kg-1 min-1 to a peak at 235 min of 11.1 +/- 1.2 mg kg-1 min-1 (p less than 0.001), compared with an increase on the control day from 2.0 +/- 0.6 to 2.5 +/- 0.6 mg kg-1 min-1 (NS) over the same period. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 152-157 3292681-4 1988 In addition, the rate of activation of glucose utilization (slope 0 to 90 minutes) was decreased (p less than 0.02) in the type I patients compared with subjects without diabetes during both the constant (0.003 +/- 0.001 mg/kg/min 2 vs 0.008 +/- 0.002 mg/kg/min 2) and variable (0.006 +/- 0.002 mg/kg/min 2 vs 0.015 +/- 0.002 mg/kg/min 2) insulin infusions. Glucose 39-46 CD59 molecule (CD59 blood group) Homo sapiens 227-232 3292681-4 1988 In addition, the rate of activation of glucose utilization (slope 0 to 90 minutes) was decreased (p less than 0.02) in the type I patients compared with subjects without diabetes during both the constant (0.003 +/- 0.001 mg/kg/min 2 vs 0.008 +/- 0.002 mg/kg/min 2) and variable (0.006 +/- 0.002 mg/kg/min 2 vs 0.015 +/- 0.002 mg/kg/min 2) insulin infusions. Glucose 39-46 CD59 molecule (CD59 blood group) Homo sapiens 258-263 3292681-4 1988 In addition, the rate of activation of glucose utilization (slope 0 to 90 minutes) was decreased (p less than 0.02) in the type I patients compared with subjects without diabetes during both the constant (0.003 +/- 0.001 mg/kg/min 2 vs 0.008 +/- 0.002 mg/kg/min 2) and variable (0.006 +/- 0.002 mg/kg/min 2 vs 0.015 +/- 0.002 mg/kg/min 2) insulin infusions. Glucose 39-46 CD59 molecule (CD59 blood group) Homo sapiens 258-263 3292681-4 1988 In addition, the rate of activation of glucose utilization (slope 0 to 90 minutes) was decreased (p less than 0.02) in the type I patients compared with subjects without diabetes during both the constant (0.003 +/- 0.001 mg/kg/min 2 vs 0.008 +/- 0.002 mg/kg/min 2) and variable (0.006 +/- 0.002 mg/kg/min 2 vs 0.015 +/- 0.002 mg/kg/min 2) insulin infusions. Glucose 39-46 CD59 molecule (CD59 blood group) Homo sapiens 258-263 3288006-3 1988 Isoflurane seemed to induce glucose intolerance (glucose disappearance rate K10-60 min = 1.628 +/- 0.462% min-1 [control] versus 1.086 +/- 0.920% min-1 [anesthesia], P less than 0.05) partly due to a decreased glucose induced insulin response. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 106-111 3288006-6 1988 Although glucose intolerance was marked during surgery (K10-60 min = 0.892 +/- 0.286% min-1), the glucose-induced insulin response remained similar to that observed in patients in group II, while growth hormone, cortisol, epinephrine, and norepinephrine concentrations increased significantly. Glucose 9-16 CD59 molecule (CD59 blood group) Homo sapiens 86-91 3285136-4 1988 In the normoglycemic state, endogenous glucose production averaged 2.15 +/- 0.13 mg x kg-1 x min-1. Glucose 39-46 CD59 molecule (CD59 blood group) Homo sapiens 93-98 3102297-6 1987 After exercise, total glucose disposal was significantly increased during the 40-mU X m-2 X min-1 infusion (P less than .05), but the increase observed during the 400-mU X m-2 X min-1 infusion was not significant. Glucose 22-29 CD59 molecule (CD59 blood group) Homo sapiens 92-97 3668074-5 1987 Glucose oxidation rate (4.35 mg kg-1 min-1) exceeded glucose intake (2.6 mg kg-1 min-1). Glucose 53-60 CD59 molecule (CD59 blood group) Homo sapiens 81-86 2878848-5 1987 Glucose disposal rates between 120 and 180 min of the clamp were 7.11 +/- 0.10 and 7.35 +/- 0.10 mg X kg-1 X min-1 with and without SRIF, respectively (difference not significant). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 109-114 3527829-3 1986 The individual fasting glucose levels were highly correlated with the elevated basal rates of hepatic glucose output (HGO) (r = 0.91, P less than .001), which fell from 138 +/- 11 to 87 +/- 5 mg X m-2 X min-1 after weight loss. Glucose 23-30 CD59 molecule (CD59 blood group) Homo sapiens 203-208 3538898-9 1986 The amount of exogenous glucose required to maintain euglycemia averaged 7.4 +/- 0.5 mg X kg-1 X min-1. Glucose 24-31 CD59 molecule (CD59 blood group) Homo sapiens 97-102 3517029-4 1986 Mean glucose disposal was 34 +/- 11, 69 +/- 10, and 84 +/- 22 mumol kg-1 min-1 in N and 16 +/- 5, 40 +/- 18, and 65 +/- 27 in IDDM, respectively. Glucose 5-12 CD59 molecule (CD59 blood group) Homo sapiens 73-78 3519651-3 1986 Endogenous glucose production declined from 2.71 +/- 0.20 mg kg-1 min-1 to 1.75 + 0.26 (P less than 0.01) and glucose utilization from 2.71 +/- 0.20 to 1.98 +/- 0.17 mg kg-1 min-1 (P less than 0.01), while blood glucose was maintained at the initial level by the infusion of glucose. Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 66-71 3519651-3 1986 Endogenous glucose production declined from 2.71 +/- 0.20 mg kg-1 min-1 to 1.75 + 0.26 (P less than 0.01) and glucose utilization from 2.71 +/- 0.20 to 1.98 +/- 0.17 mg kg-1 min-1 (P less than 0.01), while blood glucose was maintained at the initial level by the infusion of glucose. Glucose 11-18 CD59 molecule (CD59 blood group) Homo sapiens 174-179 3519651-8 1986 During control euglycemic hyperinsulinemic clamps (1 and 10 mU kg-1 min-1 insulin infusion), endogenous glucose production was suppressed at the lowest insulin infusion rate; glucose utilization increased first to 7.32 +/- 0.96 mg kg-1 min-1 and then to 16.5 +/- 1.27 mg kg-1 min-1. Glucose 104-111 CD59 molecule (CD59 blood group) Homo sapiens 68-73 3519651-8 1986 During control euglycemic hyperinsulinemic clamps (1 and 10 mU kg-1 min-1 insulin infusion), endogenous glucose production was suppressed at the lowest insulin infusion rate; glucose utilization increased first to 7.32 +/- 0.96 mg kg-1 min-1 and then to 16.5 +/- 1.27 mg kg-1 min-1. Glucose 175-182 CD59 molecule (CD59 blood group) Homo sapiens 68-73 3519651-9 1986 During euglycemic hyperinsulinemic clamps with simultaneous sodium acetoacetate infusion, similar insulin levels were attained; endogenous glucose production was also suppressed at the lowest insulin infusion rate, and insulin-stimulated glucose utilization rates (7.93 +/- 1.70 and 15.80 +/- 1.30 mg kg-1 min-1) were not modified. Glucose 238-245 CD59 molecule (CD59 blood group) Homo sapiens 306-311 3872872-14 1985 The average glucose metabolic rates of the 365 normal regions, in which gray matter regions prevailed by 20:1, was 32 mumol 100 g-1 min-1. Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 132-137 3514331-8 1986 The mean glucose utilization rate (4.70 +/- 0.36 mg X kg-1 X min-1 preglucagon) was significantly decreased by glucagon replacement (3.83 +/- 0.31 mg X kg-1 X min-1, P less than 0.02). Glucose 9-16 CD59 molecule (CD59 blood group) Homo sapiens 61-66 3514331-8 1986 The mean glucose utilization rate (4.70 +/- 0.36 mg X kg-1 X min-1 preglucagon) was significantly decreased by glucagon replacement (3.83 +/- 0.31 mg X kg-1 X min-1, P less than 0.02). Glucose 9-16 CD59 molecule (CD59 blood group) Homo sapiens 159-164 4067776-2 1985 The mean absorption rates of glucose and galactose were 26.5 and 43.8 mumol min-1 30 cm-1, respectively, and were significantly reduced (p less than 0.001) to 13 and 22%, respectively, of intake. Glucose 29-36 CD59 molecule (CD59 blood group) Homo sapiens 76-81 3905929-4 1985 glucose infusions of 0 (saline), 5 and 15 mg/kg X min-1. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 50-55 3905929-8 1985 glucose infusions of 5 and 15 mg/kg X min-1, but not when saline was infused. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 38-43 4064562-8 1985 After glucose administration, alanine release was suppressed (in all subjects) from a mean value of 153 +/- 22 to 57 +/- 16 nmol min-1 100 ml-1 of forearm (P less than 0.02) whereas that of glutamine was not significantly affected (160 +/- 30 to 143 +/- 29 nmol min-1 100 ml-1 of forearm). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 129-134 4064562-8 1985 After glucose administration, alanine release was suppressed (in all subjects) from a mean value of 153 +/- 22 to 57 +/- 16 nmol min-1 100 ml-1 of forearm (P less than 0.02) whereas that of glutamine was not significantly affected (160 +/- 30 to 143 +/- 29 nmol min-1 100 ml-1 of forearm). Glucose 6-13 CD59 molecule (CD59 blood group) Homo sapiens 262-267 4064562-11 1985 The net amino acid balance across the forearm muscle bed was negative throughout the study but decreased from a mean value of -567 in the basal state to -300 nmol min-1 100 ml-1 of forearm after glucose administration for 60 min. Glucose 195-202 CD59 molecule (CD59 blood group) Homo sapiens 163-168 3872872-15 1985 The average glucose phosphorylation rate in white matter was 20 mumol 100 g-1 min-1 with a lumped constant of 0.45. Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 78-83 3872872-16 1985 In the recently infarcted areas, the lumped constants varied from 0.37 to 2.83, corresponding to glucose metabolic rates varying from 2 to 18 mumol 100 g-1 min-1. Glucose 97-104 CD59 molecule (CD59 blood group) Homo sapiens 156-161 7116784-8 1982 Glucose turnover, assessed by the use of [6,6-2H]glucose, was 11.4 (+/- 0.9) micromol min-1 kg-1 and 11.6 (+/- 0.5) micromol min-1 kg-1 with rate of glucose was 2.3 (+/- 0.3) ml min-1 kg-1 with both isotopically labelled tracers. Glucose 49-56 CD59 molecule (CD59 blood group) Homo sapiens 86-105 6391994-6 1984 Glucose utilization was 12.7 +/- 1.4, 18.2 +/- 0.7 and 22.1 +/- 3.4 mumol X kg-1 X min-1 before treatment in the diabetic subjects, and 11.8 +/- 1.7, 20.9 +/- 3.3 and 30.1 +/- 3.6 after treatment. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 83-88 6391994-8 1984 The pre-treatment metabolic clearance rate of glucose in all diabetic studies with insulin levels greater than 30 mU/l was 2.6 +/- 0.4 and rose to 3.9 +/- 0.5 ml X kg-1 X min-1 following insulin therapy. Glucose 46-53 CD59 molecule (CD59 blood group) Homo sapiens 171-176 6542834-10 1984 In the subgroup of seven subjects in whom glucose values decreased with water intake, the mean rate of glycogen degradation was significantly lower (P less than 0.05) with the ingestion of glucose (1.3 +/- 0.4 mmol kg d.w.-1 min-1) as compared to fructose (2.1 +/- 0.5 mmol kg d.w.-1 min-1) or water (2.3 +/- 0.5 mmol kg d.w.-1 min-1). Glucose 189-196 CD59 molecule (CD59 blood group) Homo sapiens 225-230 6542834-10 1984 In the subgroup of seven subjects in whom glucose values decreased with water intake, the mean rate of glycogen degradation was significantly lower (P less than 0.05) with the ingestion of glucose (1.3 +/- 0.4 mmol kg d.w.-1 min-1) as compared to fructose (2.1 +/- 0.5 mmol kg d.w.-1 min-1) or water (2.3 +/- 0.5 mmol kg d.w.-1 min-1). Glucose 189-196 CD59 molecule (CD59 blood group) Homo sapiens 284-289 6542834-10 1984 In the subgroup of seven subjects in whom glucose values decreased with water intake, the mean rate of glycogen degradation was significantly lower (P less than 0.05) with the ingestion of glucose (1.3 +/- 0.4 mmol kg d.w.-1 min-1) as compared to fructose (2.1 +/- 0.5 mmol kg d.w.-1 min-1) or water (2.3 +/- 0.5 mmol kg d.w.-1 min-1). Glucose 189-196 CD59 molecule (CD59 blood group) Homo sapiens 284-289 6242816-2 1984 At an insulin infusion rate of 1 mU/kg/min, insulin mediated glucose disposal was significantly greater (p less than 0.02) following delivery (1.194 +/- 0.138 mmol/m2/min) than in pregnancy (0.761 +/- 0.072 mmol/m2/min) and the rate of decline in insulin mediated glucose disposal, at the end of the insulin infusion, was significantly greater (p less than 0.02) following delivery (24.78 +/- 4.22 mumol/m2/min2) than in pregnancy (15.17 +/- 2.00 mumol/m2/min2). Glucose 61-68 CD59 molecule (CD59 blood group) Homo sapiens 407-411 6242816-2 1984 At an insulin infusion rate of 1 mU/kg/min, insulin mediated glucose disposal was significantly greater (p less than 0.02) following delivery (1.194 +/- 0.138 mmol/m2/min) than in pregnancy (0.761 +/- 0.072 mmol/m2/min) and the rate of decline in insulin mediated glucose disposal, at the end of the insulin infusion, was significantly greater (p less than 0.02) following delivery (24.78 +/- 4.22 mumol/m2/min2) than in pregnancy (15.17 +/- 2.00 mumol/m2/min2). Glucose 61-68 CD59 molecule (CD59 blood group) Homo sapiens 456-460 6430379-3 1984 Glucose at 5 mg kg-1 min-1 reduced urea excretion compared with glucose at 1 mg kg-1 min-1. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 21-26 6430379-3 1984 Glucose at 5 mg kg-1 min-1 reduced urea excretion compared with glucose at 1 mg kg-1 min-1. Glucose 64-71 CD59 molecule (CD59 blood group) Homo sapiens 85-90 6431122-2 1984 Caloric intake was twice the predicted basal metabolic rate, with 5 mg kg-1 min-1 of glucose, 2.5 g kg-1 day-1 of amino acid and the remainder of calories supplied as a fat emulsion. Glucose 85-92 CD59 molecule (CD59 blood group) Homo sapiens 76-81 6344653-5 1983 min-1 for plasma glucose concentrations of 60, 95, and 160 mg/dl, respectively) produced a linear Eadie-Hofstee plot, suggesting that insulin-independent glucose uptake followed Michaelis-Menten kinetics. Glucose 17-24 CD59 molecule (CD59 blood group) Homo sapiens 0-5 6344653-5 1983 min-1 for plasma glucose concentrations of 60, 95, and 160 mg/dl, respectively) produced a linear Eadie-Hofstee plot, suggesting that insulin-independent glucose uptake followed Michaelis-Menten kinetics. Glucose 154-161 CD59 molecule (CD59 blood group) Homo sapiens 0-5 456773-3 1979 The rates of appearance of glucose and of free fatty acids were increased in the diabetics to 17.6 and 10.2 micronmol min-1 kg-1 respectively. Glucose 27-34 CD59 molecule (CD59 blood group) Homo sapiens 118-128 6790281-3 1981 Glucose is utilized at a rate of 1.1 mumol x min-1 x g cells-1. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 45-50 7238507-7 1981 V for cyclohexaamylase was found to be about 14-15 mumol glucose min-1 (mg pure protein)-1, the Km for cyclohexaamylose was 0.142 mM. Glucose 57-64 CD59 molecule (CD59 blood group) Homo sapiens 65-90 6819169-1 1982 This study was designed to evaluate the influence of intravenous infusion (72 mg min-1) of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin synthesis, on glucose homeostasis in normal man. Glucose 177-184 CD59 molecule (CD59 blood group) Homo sapiens 81-86 7075153-6 1982 The rate of appearance of glucose and urea in the plasma was rapidly reduced by the 17.7 mumol min-1 kg-1 glucose infusion. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 95-105 7075153-6 1982 The rate of appearance of glucose and urea in the plasma was rapidly reduced by the 17.7 mumol min-1 kg-1 glucose infusion. Glucose 106-113 CD59 molecule (CD59 blood group) Homo sapiens 95-105 32385603-12 2020 RESULTS: Glucose MCR/I was significantly higher during IGIVI than during oral glucose administration, independently of glycaemic status (12 +- 6 for IGIVI vs 7.4 +- 3 ml min-1 kg-1 per nmol/l for oral, p< 0.001 from paired t test). Glucose 9-16 CD59 molecule (CD59 blood group) Homo sapiens 170-180 29190340-6 2018 In response to insulin-induced hypoglycemia, endogenous glucose production did not change from before to 6 months (0.42 +- 0.08 vs 0.54 +- 0.07 mg kg-1 min-1) but improved after 18 months (0.84 +- 0.15 mg kg-1 min-1; P < 0.05 vs before CGM), albeit remaining less than in controls (1.39 +- 0.11 mg kg-1 min-1; P <= 0.01 vs all). Glucose 56-63 CD59 molecule (CD59 blood group) Homo sapiens 210-215 29560563-4 2018 A normalized coefficient of variation of quantitative glucose influx constant, calculated as the ratio: standard deviation of the segmental Ki (min-1)/global Ki (min-1) was determined using a validated software (Carimas 2.4, Turku PET Centre). Glucose 54-61 CD59 molecule (CD59 blood group) Homo sapiens 144-149 29560563-4 2018 A normalized coefficient of variation of quantitative glucose influx constant, calculated as the ratio: standard deviation of the segmental Ki (min-1)/global Ki (min-1) was determined using a validated software (Carimas 2.4, Turku PET Centre). Glucose 54-61 CD59 molecule (CD59 blood group) Homo sapiens 162-167 29190340-6 2018 In response to insulin-induced hypoglycemia, endogenous glucose production did not change from before to 6 months (0.42 +- 0.08 vs 0.54 +- 0.07 mg kg-1 min-1) but improved after 18 months (0.84 +- 0.15 mg kg-1 min-1; P < 0.05 vs before CGM), albeit remaining less than in controls (1.39 +- 0.11 mg kg-1 min-1; P <= 0.01 vs all). Glucose 56-63 CD59 molecule (CD59 blood group) Homo sapiens 210-215 30353450-6 2019 The rate of glucose utilisation during exercise was also significantly reduced (85.76 +- 23.95 vs. 56.67 +- 15.09 muM kg-1 min-1). Glucose 12-19 CD59 molecule (CD59 blood group) Homo sapiens 123-128 31458409-7 2018 The cell power increased with the increasing flow rate of the glucose solution up to 50 cm3 min-1 and leveled off thereafter. Glucose 62-69 CD59 molecule (CD59 blood group) Homo sapiens 92-97 28230742-1 2017 Peak exogenous carbohydrate oxidation rates typically reach ~1 g min-1 during exercise when ample glucose or glucose polymers are ingested. Glucose 98-105 CD59 molecule (CD59 blood group) Homo sapiens 65-70 28230742-1 2017 Peak exogenous carbohydrate oxidation rates typically reach ~1 g min-1 during exercise when ample glucose or glucose polymers are ingested. Glucose 109-116 CD59 molecule (CD59 blood group) Homo sapiens 65-70 28230742-7 2017 We conclude that fructose co-ingestion (0.6 g min-1) with glucose (1.2 g min-1) provided either as a monosaccharide or as sucrose strongly increases exogenous carbohydrate oxidation rates during prolonged exercise in trained cyclists. Glucose 58-65 CD59 molecule (CD59 blood group) Homo sapiens 73-78 28155845-6 2017 We simulated the flow velocity, shear stress and diffusion of glucose molecules inside and outside the culture chambers under a continuous flow rate of 1 mul min-1. Glucose 62-69 CD59 molecule (CD59 blood group) Homo sapiens 158-163 27709794-6 2017 Glucose (AUCglucose 319 +- 30 [placebo] vs 315 +- 18 mmol.L-1 .min-1 [sitagliptin], Delta 7 [95% confidence interval -50 to 63] mmol.L-1 .min-1 ), insulin, C-peptide and glucagon concentrations were not affected significantly by sitagliptin treatment ( P = .60-1.00). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 63-68 27840416-7 2017 RESULTS: In both the groups (P<0.001), the incremental areas under the curve (iAUC)0-60 min for glucose was greater with the 3 kcal min-1 than the 1 kcal min-1 infusion; the iAUC0-120 min for glucose during 3 kcal min-1 was greater (P<0.05), in the obese. Glucose 99-106 CD59 molecule (CD59 blood group) Homo sapiens 135-140 27840416-7 2017 RESULTS: In both the groups (P<0.001), the incremental areas under the curve (iAUC)0-60 min for glucose was greater with the 3 kcal min-1 than the 1 kcal min-1 infusion; the iAUC0-120 min for glucose during 3 kcal min-1 was greater (P<0.05), in the obese. Glucose 99-106 CD59 molecule (CD59 blood group) Homo sapiens 157-162 27840416-7 2017 RESULTS: In both the groups (P<0.001), the incremental areas under the curve (iAUC)0-60 min for glucose was greater with the 3 kcal min-1 than the 1 kcal min-1 infusion; the iAUC0-120 min for glucose during 3 kcal min-1 was greater (P<0.05), in the obese. Glucose 99-106 CD59 molecule (CD59 blood group) Homo sapiens 157-162 27840416-7 2017 RESULTS: In both the groups (P<0.001), the incremental areas under the curve (iAUC)0-60 min for glucose was greater with the 3 kcal min-1 than the 1 kcal min-1 infusion; the iAUC0-120 min for glucose during 3 kcal min-1 was greater (P<0.05), in the obese. Glucose 195-202 CD59 molecule (CD59 blood group) Homo sapiens 135-140 28043929-4 2017 RESULTS: The glucose disposal rate (M value) increased significantly at 3 months after RYGB (from 3.36 +- 1.26 mg kg-1 min-1 to 6.30 +- 1.3 mg kg-1 min-1, p < 0.001). Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 119-124 28043929-4 2017 RESULTS: The glucose disposal rate (M value) increased significantly at 3 months after RYGB (from 3.36 +- 1.26 mg kg-1 min-1 to 6.30 +- 1.3 mg kg-1 min-1, p < 0.001). Glucose 13-20 CD59 molecule (CD59 blood group) Homo sapiens 148-153 27709794-6 2017 Glucose (AUCglucose 319 +- 30 [placebo] vs 315 +- 18 mmol.L-1 .min-1 [sitagliptin], Delta 7 [95% confidence interval -50 to 63] mmol.L-1 .min-1 ), insulin, C-peptide and glucagon concentrations were not affected significantly by sitagliptin treatment ( P = .60-1.00). Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 138-143 26373645-10 2015 To conclude, ingesting 0.5-1.0:1-ratio fructose:glucose/maltodextrin beverages at 1.3-2.4 g min(-1) likely benefits 2.5-3.0 h endurance power versus isocaloric single saccharide. Glucose 48-55 CD59 molecule (CD59 blood group) Homo sapiens 92-98 27809324-6 2016 This microfluidic fuel cell is able to generate a voltage up to ~450 mV from 10 mM of glucose with a flow rate of 20 muL min-1. Glucose 86-93 CD59 molecule (CD59 blood group) Homo sapiens 121-126 27336358-10 2016 Before surgery, beta-cell glucose sensitivity was higher in PPHG than No-PPHG in both RYGB (118 +- 67 vs 65 +- 24 pmol/min-1 m2 mM-1) and LSG patients (114 +- 32 vs 86 +- 33) (both P = .02) and improved in all subjects after surgery. Glucose 26-33 CD59 molecule (CD59 blood group) Homo sapiens 119-124 27941058-3 2017 Glucose (3 kcal min-1) was infused via an intraduodenal manometry catheter for 60 min. Glucose 0-7 CD59 molecule (CD59 blood group) Homo sapiens 16-21 24726385-7 2014 CD59 expression is reduced by glucose and in rodent diabetes models but upregulated in human diabetic islets, potentially reflecting compensatory reactions. Glucose 30-37 CD59 molecule (CD59 blood group) Homo sapiens 0-4